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Gram	  Staining:	  Gram	  positive(3)	  
Morphology:	  Bacillus(4)	  	  
Spore	  Formation:	  Yes(3,	  5)	  
Spore	  Characteristics:	  Antibiotic-­‐resistant(5,	  6),	  Alcohol-­‐resistant(3,	  5,	  7),	  Aero	  tolerant(5).	  Heat-­‐resistant	  (600C	  for	  24	  hours)(7).	  
Motility:	  Motile(4),	  Flagellated(8-­‐11).	  Flagellar	  components	  have	  been	  implicated	  in	  adherence	  and	  colonization	  in	  the	  host(8,	  12,	  13),	  but	  data	  is	  conflicting	  and	  inconclusive.	  
Aerotolerance:	  Obligate	  Anaerobe(4,	  14)	  
Vegetative	  Propagation:	  Grows	  well	  at	  370C	  in	  the	  absence	  of	  oxygen(14)	  
Doubling	  Time:	  40-­‐70	  minutes(15)	  
Virulence	  Factors:	  Two	  large	  clostridial	  toxins,	  TcdA(308kDa)	  and	  TcdB(270kDa)(3).	  Binary	  toxin	  (CDT)	  found	  in	  a	  low	  percentage	  of	  strains	  as	  well(3,	  16).	  
Genetic	  Features:	  Pathogenicity	  Locus	  (PaLoc).	  19.6	  kilobases	  long.	  Contains	  tcdA	  and	  tcdB	  genes	  (encoding	  TcdA	  and	  TcdB).	  Also	  contains	  tcdE	  (encodes	  a	  holin	  permitting	  toxin	  release),	  and	  tcdD	  and	  tcdC,	  positive	  and	  negative	  regulators	  of	  the	  locus	  respectively(3,	  17,	  18).	  Cdt	  locus	  (CdtLoc).	  Encodes	  the	  two	  subunits	  of	  binary	  toxin,	  cdtA	  and	  cdtB,	  as	  well	  as	  cdtR,	  a	  putative	  regulator	  of	  the	  locus.	  Found	  in	  only	  a	  small	  percentage	  of	  C.	  difficile	  stains(3,	  19,	  20).	  	  
Genome	  Size:	  4.29	  megabases(21)	  
Antibiotic	  Resistance	  (Reported):	  Bacitracin,	  Daunorubicin,	  Nogalamycin,	  Erythromycin,	  Clindamycin,	  Gentamicin,	  Tetracycline,	  Ampicillin,	  Cefotaxime,	  Cefoxitin,	  Cefuroxime(21).	  Cycloserine(14).	  
Antibiotic	  Sensitivity	  (Reported):	  Teicoplanin,	  Vancomycin(21).	  
Strains	  Used	  in	  This	  Dissertation:	  VPI	  10463:	  ATCC	  43255	  630:	  ATCC	  BAA-­‐1382	  
Representative	  Genomes:	  VPI	  10463:	  GenBank	  Accession	  Number:	  NZ_ABKJ00000000.2	  630:	  GenBank	  Accession	  Number:	  AM180355	  
	  
Table	  1:	  Microbiological	  Characteristics	  of	  Clostridium	  difficile	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Clinical	  Significance	  of	  Clostridium	  difficile	  
Clostridium	  difficile	  (C.	  difficile)	  is	  a	  Gram-­‐positive	  spore-­‐forming	  obligate	  anaerobic	  bacterium	  (Table	  1)	  and	  is	  a	  causative	  agent	  of	  antibiotic-­‐associated	  diarrhea	  and	  the	  major	  causative	  agent	  of	  antibiotic	  associated	  pseudomembranous	  colitis(22-­‐24).	  Though	  C.	  difficile	  was	  first	  described	  in	  1935	  after	  its	  isolation	  from	  the	  feces	  of	  healthy	  infants(22-­‐24),	  it	  was	  not	  until	  the	  late	  1970s	  when	  a	  series	  of	  experiments	  with	  clindamycin-­‐treated	  hamsters	  identified	  C.	  difficile	  as	  the	  causative	  agent	  of	  antibiotic-­‐associated	  pseudomembranous	  colitis(22,	  25,	  26).	  Subsequent	  studies	  have	  revealed	  that	  colonization	  with	  C.	  difficile	  was	  associated	  with	  a	  broad	  array	  of	  clinical	  outcomes	  in	  patients:	  from	  asymptomatic	  colonization	  to	  diarrhea	  to	  severe	  outcomes	  including	  pseudomembranous	  colitis	  and	  fulminant	  colitis(23,	  27,	  28).	  Indeed,	  despite	  C.	  difficile	  being	  first	  described	  as	  a	  human	  pathogen	  in	  relation	  to	  pseudomembranous	  colitis,	  less	  than	  half	  of	  all	  patients	  infected	  with	  C.	  difficile	  actually	  develop	  pseudomembranous	  colitis(23,	  29,	  30).	  	  	   The	  prevalence	  and	  severity	  of	  C.	  difficile	  infection	  in	  patients	  has	  increased	  considerably	  in	  recent	  years(23,	  31,	  32).	  The	  incidence	  of	  C.	  difficile	  infection	  in	  the	  US	  has	  drastically	  increased	  in	  recent	  years	  from	  less	  than	  150,000	  cases	  in	  2000	  to	  nearly	  350,000	  cases	  reported	  in	  2010(31).	  The	  higher	  incidence	  of	  disease	  has	  also	  been	  associated	  with	  an	  increase	  in	  mortality	  attributable	  to	  C.	  difficile	  infection:	  while	  C.	  difficile	  was	  associated	  with	  less	  than	  6	  deaths	  per	  one	  million	  population	  in	  1999,	  by	  2004	  that	  number	  had	  climbed	  to	  nearly	  24	  deaths	  per	  one	  million	  population(23,	  32).	  All	  told,	  C.	  difficile	  infection	  is	  estimated	  to	  be	  responsible	  for	  at	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least	  14,000	  deaths	  and	  $1	  billion	  in	  healthcare-­‐associated	  costs	  annually	  in	  the	  United	  States(33-­‐35),	  underscoring	  the	  clinical	  importance	  of	  this	  disease.	  	  	   In	  recent	  years,	  it	  has	  been	  suggested	  that	  the	  emergence	  of	  so-­‐called	  “hypervirulent”	  B1/NAP1/027	  strains	  of	  C.	  difficile	  may	  be	  at	  least	  partly	  responsible	  for	  the	  increased	  frequency	  of	  C.	  difficile	  infection(36,	  37).	  In	  addition	  to	  resistance	  to	  fluoroquinolones(36,	  37),	  preliminary	  studies	  suggested	  that	  these	  “hypervirulent”	  isolates	  produced	  much	  higher	  levels	  of	  both	  TcdA	  and	  TcdB	  as	  compared	  to	  other	  clinical	  isolates(37,	  38).	  Furthermore,	  NAP1/027	  strains	  were	  also	  reported	  to	  sporulate	  at	  a	  faster	  rate	  and	  produce	  more	  spores	  overall	  than	  other	  C.	  difficile	  strains(37,	  39,	  40).	  Additionally,	  a	  recent	  study	  by	  Carlson	  Jr.	  and	  colleagues	  using	  a	  large	  collection	  of	  ribotype	  027	  strains	  found	  that	  in	  aggregate,	  ribotype	  027	  strains	  did	  not	  produce	  more	  spores	  than	  other	  C.	  difficile	  strains	  in	  
vitro(41).	  However,	  C.	  difficile	  isolates	  from	  cases	  of	  severe	  disease	  produced	  significantly	  higher	  numbers	  of	  spores	  than	  all	  other	  strains	  assayed,	  suggesting	  that	  spore	  production,	  independent	  of	  ribotype,	  may	  contribute	  to	  the	  severity	  of	  C.	  
difficile	  infection(41).	  	   The	  main	  virulence	  factors	  of	  C.	  difficile	  are	  two	  large	  clostridial	  toxins,	  named	  TcdA	  and	  TcdB(18,	  23,	  27,	  42).	  Both	  of	  these	  toxins	  are	  glycosyltransferases,	  which	  glucosylate	  and	  irrevocably	  inactivate	  small	  GTPases	  including	  Rho,	  Rac,	  and	  Cdc42	  within	  target	  cells(18,	  42).	  Upon	  binding	  to	  a	  target	  cell,	  both	  toxins	  are	  endocytosed	  and	  undergo	  a	  conformational	  change	  within	  the	  endosome(42-­‐45).	  Though	  the	  process	  is	  better	  understood	  for	  TcdB,	  the	  internalization	  toxin	  ultimately	  results	  in	  the	  release	  of	  the	  N-­‐terminal	  glucosyltransferase	  domain	  of	  the	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toxin	  into	  the	  host	  cytosol(42,	  46-­‐48).	  Intoxication	  of	  eukaryotic	  cells	  with	  C.	  difficile	  toxin	  results	  in	  cell	  rounding	  and	  loss	  of	  cell	  membrane	  integrity,	  as	  well	  as	  cell	  death(18,	  49,	  50).	  	  
Pathogenesis	  of	  C.	  difficile	  	  	   C.	  difficile	  was	  first	  identified	  as	  a	  causative	  agent	  of	  pseudomembranous	  colitis	  in	  the	  hamster	  model(22,	  25,	  26),	  and	  many	  investigations	  into	  the	  pathogenesis	  of	  C.	  difficile	  have	  been	  performed	  using	  this	  same	  model(51-­‐56).	  As	  infection	  of	  hamsters(57,	  58)	  or	  mice(59)	  with	  non-­‐toxigenic	  (TcdA	  and	  TcdB	  negative)	  strains	  of	  C.	  difficile	  does	  not	  result	  in	  disease,	  and	  indeed	  precolonization	  of	  hamsters	  with	  non-­‐toxin	  producing	  strains	  of	  C.	  difficile	  prevents	  the	  development	  disease	  upon	  challenge	  with	  toxigenic	  C.	  difficile	  strains(53,	  57),	  many	  studies	  have	  focused	  on	  the	  role	  of	  C.	  difficile	  toxins	  in	  disease(51,	  52,	  56,	  58,	  60).	  However,	  many	  of	  these	  investigations	  have	  produced	  conflicting	  results.	  In	  one	  study	  genetic	  deletion	  of	  TcdB,	  but	  not	  TcdA,	  resulted	  a	  drastic	  decrease	  in	  mortality	  following	  infection	  with	  TcdB	  deficient	  mutants	  in	  an	  acutely	  fatal	  hamster	  model	  in	  one	  study(52).	  Additionally,	  numerous	  studies	  have	  demonstrated	  that	  C.	  difficile	  strains	  producing	  only	  TcdB	  are	  still	  capable	  of	  producing	  high	  levels	  of	  morbidity	  and	  mortality	  in	  clindamycin	  treated	  hamsters(51,	  61).	  A	  subsequent	  study	  using	  TcdA	  or	  TcdB	  deficient	  mutants	  reported	  near	  identical	  mortality	  following	  infection	  of	  hamsters	  with	  strains	  expressing	  each	  toxin	  alone(58).	  While	  initial	  studies	  using	  strains	  of	  C.	  difficile	  deficient	  in	  TcdA	  and	  TcdB	  but	  positive	  for	  binary	  toxin	  indicated	  no	  role	  for	  binary	  toxin	  in	  promoting	  morbidity	  or	  mortality	  in	  
	   6	  
hamsters(56),	  a	  recent	  study	  has	  reported	  mortality	  following	  infection	  of	  hamsters	  with	  C.	  difficile	  expressing	  binary	  toxin	  but	  not	  TcdA	  and	  TcdB	  (60).	  Thus,	  while	  disease	  as	  a	  result	  of	  C.	  difficile	  infection	  is	  most	  certainly	  toxin-­‐mediated,	  the	  relative	  importance	  of	  each	  individual	  toxin	  in	  driving	  disease	  development	  is	  unclear.	  	  	  	  
Colonization	  Resistance,	  the	  Microbiome,	  and	  Antibiotics	  	   The	  microbiome	  provides	  numerous	  nutritional	  benefits	  to	  the	  host,	  including	  synthesizing	  vitamins(62)	  and	  short	  chain-­‐fatty	  acids	  (SCFAs)(63),	  and	  the	  presence	  of	  the	  microbiome	  is	  also	  vitally	  important	  for	  the	  development	  and	  functionality	  of	  the	  intestinal	  immune	  system(64,	  65).	  Additionally,	  the	  presence	  of	  the	  microbiome	  within	  the	  gastrointestinal	  tract	  limits	  the	  ability	  of	  pathogens,	  including	  C.	  difficile,	  to	  persist	  within	  the	  gut	  and	  cause	  disease,	  a	  phenomenon	  known	  as	  colonization	  resistance(66,	  67).	  	   Alteration	  of	  the	  intestinal	  microbiome	  through	  the	  use	  of	  antibiotics	  is	  commonly	  associated	  with	  increased	  susceptibility	  to	  intestinal	  pathogens(68-­‐70).	  Metronidazole	  treatment	  markedly	  alters	  the	  composition	  of	  the	  colonic	  microbiota	  and	  is	  associated	  with	  increased	  disease	  severity	  during	  C.	  rodentium	  colitis(70).	  Antibiotic	  treatment	  also	  permits	  efficient	  Campylobacter	  jejuni	  infection	  in	  mice(69),	  as	  well	  as	  the	  development	  of	  acute	  typhlocolitis	  following	  Salmonella	  
typhimurium	  infection(68).	  	  Furthermore,	  disruption	  of	  the	  intestinal	  microbiota	  by	  host	  inflammatory	  responses	  also	  permits	  the	  expansion	  of	  members	  of	  the	  Family	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Enterobacteriaceae(71),	  highlighting	  the	  potential	  for	  unwanted	  bacterial	  overgrowth	  following	  disruption	  of	  the	  normal	  microbiota.	  	  	   The	  intestinal	  microbiome	  controls	  the	  susceptibility	  of	  experimental	  animals	  to	  C.	  difficile	  colonization	  and	  infection.	  Under	  normal	  conditions	  mice	  are	  refractory	  to	  C.	  difficile	  infection(66,	  72),	  however,	  antibiotic	  administration	  permits	  subsequent	  C.	  difficile	  colonization	  and	  the	  development	  of	  intestinal	  disease(59,	  66,	  72-­‐82).	  Antibiotic	  treatments	  that	  permit	  C.	  difficile	  infection	  are	  associated	  with	  marked	  alterations	  in	  the	  composition	  and	  diversity,	  but	  not	  overall	  bacterial	  density,	  of	  the	  intestinal	  microbiome(66,	  70,	  73,	  80,	  83).	  Alterations	  in	  the	  structure	  of	  the	  microbiome	  are	  also	  associated	  with	  increased	  levels	  of	  certain	  metabolites,	  including	  taurocholate,	  succinate,	  and	  fructose,	  which	  can	  be	  utilized	  by	  C.	  difficile	  for	  outgrowth(83,	  84),	  suggesting	  a	  potential	  mechanism	  of	  colonization	  resistance	  to	  C.	  difficile.	  	  
	  
Structure	  and	  Cellular	  Composition	  of	  The	  Intestines	  	  The	  gastrointestinal	  tract	  is	  the	  largest	  environment-­‐exposed	  surface	  area	  in	  the	  body,	  and	  is	  in	  direct	  contact	  with	  a	  large	  and	  varied	  microbial	  community(85).	  Fortunately,	  the	  gastrointestinal	  tract	  is	  also	  home	  to	  a	  large	  variety	  of	  immune	  cells	  and	  structures	  that	  help	  maintain	  intestinal	  homeostasis	  in	  the	  face	  of	  microbial	  challenge(86-­‐88).	  Intestinal	  epithelial	  cells	  physically	  separate	  underlying	  tissues	  from	  the	  intestinal	  lumen(89,	  90),	  while	  goblet	  cells	  maintain	  a	  mucus	  layer	  to	  prevent	  microbial	  contact	  with	  epithelial	  cells(91,	  92).	  Leukocytes	  beneath	  the	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epithelial	  cell	  layer	  can	  both	  promote	  or	  inhibit	  inflammatory	  responses(93-­‐96),	  and	  are	  efficiently	  organized	  into	  effector	  and	  inductive	  sites(97-­‐99).	  This	  organization	  largely	  prevents	  unwanted	  inflammation	  while	  retaining	  the	  ability	  to	  respond	  rapidly	  to	  a	  wide	  array	  of	  perturbations.	  	  	  	   The	  intestinal	  epithelium	  is	  actually	  a	  single	  layer	  of	  cells,	  all	  of	  which	  are	  derived	  from	  multipotent	  stem	  cells	  located	  within	  the	  intestinal	  crypts(86,	  90).	  Collectively,	  these	  cells	  are	  responsible	  for	  nutrient	  absorption,	  physical	  exclusion	  of	  luminal	  contents	  from	  underlying	  tissues,	  antimicrobial	  peptide	  production,	  and	  maintenance	  of	  the	  intestinal	  mucus	  layer(86,	  90).	  
Columnar	  epithelial	  cells	  constitute	  the	  majority	  of	  cells	  present	  in	  the	  intestinal	  epithelium(90,	  100).	  Enterocytes	  provide	  a	  physical	  barrier	  separating	  the	  luminal	  contents	  of	  the	  GI	  tract	  from	  underlying	  tissues,	  as	  well	  as	  participating	  in	  the	  absorption	  of	  materials	  from	  lumen(89,	  90).	  Epithelial	  cells	  directly	  participate	  in	  immunological	  surveillance	  and	  direction	  of	  host	  responses	  in	  the	  gut.	  Epithelial	  cells	  can	  express	  numerous	  Pattern	  Recognition	  Receptors	  (PRRS),	  including	  TLR5(101),	  TLR1,	  TLR2,	  TLR3,	  TLR9(86),	  and	  NOD2(89),	  and	  can	  produce	  chemotactic	  factors	  for	  both	  myeloid	  and	  lymphoid	  cells	  following	  inflammatory	  stimulation(102).	  IL-­‐17	  stimulation	  of	  intestinal	  epithelial	  cells	  can	  drive	  the	  expression	  of	  neutrophil	  chemokines(103).	  Epithelial	  cells	  can	  produce	  anti-­‐microbial	  peptides,	  such	  as	  CRAMP,	  to	  directly	  influence	  microbial	  populations	  in	  the	  lumen	  of	  the	  gut(104).	  Additionally,	  epithelial	  cells	  can	  interact	  with	  leukocyte	  populations	  through	  the	  expression	  of	  both	  MHCII(105)	  and	  MHCI(106).	  Therefore,	  enterocytes	  play	  a	  key	  role	  in	  not	  only	  preventing	  microbes	  and	  microbial	  products	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from	  penetrating	  to	  underlying	  tissues,	  but	  also	  initiating	  and	  directing	  inflammatory	  responses.	  	  	  	  
Goblet	  cells	  are	  another	  class	  of	  specialized	  epithelial	  cells	  found	  in	  the	  intestinal	  epithelium(100,	  107).	  While	  goblet	  cells	  can	  be	  found	  in	  both	  the	  small	  and	  large	  intestines,	  they	  represent	  approximately	  15	  percent	  of	  the	  cells	  found	  in	  the	  large	  intestine	  epithelium(100,	  107).	  Goblet	  cells	  contain	  large	  mucus-­‐laden	  vacuoles(107),	  and	  express	  high	  levels	  of	  the	  MUC2	  gene(91).	  MUC2	  is	  the	  major	  structural	  component	  of	  both	  intestinal	  mucus	  layers(108).	  The	  lower	  mucus	  layer	  makes	  direct	  contact	  with	  the	  intestinal	  epithelium	  and	  is	  rarely	  contaminated	  with	  bacteria,	  while	  the	  outer	  layer	  contacts	  the	  intestinal	  lumen	  and	  the	  intestinal	  microbiome(92).	  Goblet	  cells	  have	  also	  recently	  been	  found	  to	  produce	  the	  antimicrobial	  peptides	  Ang4,	  RegIIIγ	  and	  RegIIIβ(109,	  110).	  RegIIIγ	  activity	  is	  especially	  important	  in	  preventing	  microbial	  contact	  with	  the	  underlying	  epithelium(111).	  Goblet	  cells	  may	  also	  transfer	  antigens	  acquired	  in	  the	  intestinal	  lumen	  to	  dendritic	  cells	  in	  the	  lamina	  propria(112).	  These	  studies	  have	  demonstrated	  a	  potential	  role	  for	  goblet	  cells	  beyond	  mucus	  production	  by	  participating	  directly	  in	  the	  uptake	  of	  antigen	  and	  influencing	  the	  development	  of	  inflammatory	  responses.	  Within	  the	  intestinal	  epithelium	  resides	  a	  population	  of	  lymphocytes	  referred	  to	  as	  Intraepithelial	  lymphocytes	  (IEL)(113).	  Almost	  all	  IELs	  are	  T	  cells,	  with	  both	  αβ+	  and	  γδ+	  populations	  represented(113,	  114).	  Adherence	  of	  IELs	  to	  epithelial	  cells	  is	  mediated	  by	  interactions	  between	  CD103	  expressed	  on	  IELS,	  and	  E-­‐cadherin	  expressed	  on	  epithelial	  cells(115).	  Many	  IELs	  at	  baseline	  display	  a	  mixed	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phenotype,	  with	  expression	  of	  some	  activation	  markers	  but	  not	  others(116).	  However,	  following	  stimulation,	  IELs	  become	  activated	  and	  express	  effector	  cytokines	  including	  IFNγ	  and	  KGF(116-­‐118).	  IELs	  can	  exert	  both	  protective	  and	  pathogenic	  roles	  during	  inflammation:	  while	  IEL-­‐derived	  KGF	  is	  believed	  to	  protect	  the	  epithelium	  from	  damage	  during	  chemically	  induced	  colitis(119),	  IELs	  producing	  IFNγ	  and	  TNFα	  have	  been	  associated	  with	  the	  development	  of	  inflammatory	  bowel	  disease(120).	  The	  proximity	  of	  IELs	  to	  the	  lumen	  of	  the	  gut,	  and	  their	  ability	  to	  rapidly	  produce	  both	  inflammatory	  and	  epithelial-­‐protective	  signals,	  make	  them	  key	  “first	  line”	  defenders	  in	  the	  intestinal	  tract.	  	  	  Underlying	  the	  intestinal	  epithelium	  is	  the	  lamina	  propria,	  an	  area	  rich	  in	  B	  and	  T	  lymphocytes(86).	  In	  contrast	  to	  Peyer’s	  patches,	  which	  are	  inductive	  sites	  for	  the	  priming	  of	  lymphocytes,	  the	  lamina	  propria	  is	  an	  effector	  site	  where	  activated	  lymphocytes	  respond	  to	  appropriate	  stimulation(97-­‐99).	  αβ	  TCR+	  T-­‐cells	  are	  the	  most	  common	  lymphocyte	  within	  the	  small	  intestinal	  lamina	  propria(114).	  In	  keeping	  with	  the	  effector	  function	  of	  the	  lamina	  propria,	  T-­‐cells	  found	  within	  the	  lamina	  propria	  express	  markers	  indicative	  of	  activation,	  including	  high	  levels	  of	  CD69	  and	  CD25	  (121),	  as	  well	  as	  spontaneously	  secreting	  of	  IL-­‐4	  and	  IFNγ(122).	  Subsets	  within	  this	  population	  have	  drastically	  different	  activities:	  while	  CD4+	  CD25+	  regulatory	  T-­‐cells	  in	  the	  lamina	  propria	  can	  inhibit	  T-­‐cell	  proliferation,	  cytokine	  production	  and	  the	  development	  of	  colitis(94,	  95),	  lamina	  propria	  CD4+	  T-­‐cells	  can	  secrete	  both	  IL-­‐17	  and	  IL-­‐22	  and	  are	  associated	  with	  the	  development	  of	  intestinal	  inflammation(93,	  96).	  Therefore,	  lamina	  propria	  T-­‐cells	  have	  the	  ability	  to	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rapidly	  react	  to	  signals	  received	  from	  the	  luminal	  environment	  and	  initiate	  both	  inflammatory	  and	  anti-­‐inflammatory	  responses.	  In	  contrast	  to	  the	  small	  intestine,	  B-­cells	  are	  the	  predominant	  lymphocyte	  present	  in	  the	  lamina	  propria	  of	  the	  large	  intestine(114).	  Lamina	  propria	  B-­‐cells	  secrete	  dimeric	  IgA,	  which	  is	  trancytosed	  through	  epithelial	  cells	  to	  the	  lumen	  of	  the	  gut	  through	  the	  action	  of	  the	  polymeric	  immunoglobulin	  receptor	  (pIgR)(123,	  124).	  While	  antigen-­‐specific	  IgA	  can	  be	  generated	  during	  intestinal	  infection(125),	  intestinal	  IgA	  secretion	  also	  plays	  a	  key	  role	  at	  baseline	  by	  inhibiting	  the	  penetration	  of	  commensal	  microbes	  through	  the	  epithelium	  and	  enhancing	  the	  uptake	  of	  luminal	  bacterial	  by	  M-­‐cells(123).	  Intestinal	  IgA	  can	  also	  directly	  modulate	  the	  composition	  of	  the	  intestinal	  microbiome(126),	  highlighting	  the	  key	  role	  of	  IgA	  and	  lamina	  propria	  B-­‐cells	  in	  shaping	  both	  the	  membership	  and	  location	  of	  the	  microbiome.	  	  	  
Lamina	  propria	  dendritic	  cells	  (LPDCs)	  play	  a	  large	  role	  in	  determining	  whether	  the	  response	  to	  a	  particular	  antigen	  will	  be	  inflammatory	  or	  anti-­‐inflammatory.	  LPDCs	  capture	  luminal	  antigen	  by	  extending	  their	  processes	  through	  the	  epithelial	  cell	  layer,	  a	  process	  dependent	  on	  CX3CR1(127).	  There	  are	  two	  broad	  classifications	  of	  LPDCs	  to	  consider:	  CD103+	  and	  CD103-­‐.	  CD103+	  LPDCS	  promote	  the	  generation	  of	  Foxp3+	  regulatory	  T-­‐cells	  through	  the	  secretion	  of	  retinoic	  acid	  and	  in	  combination	  with	  TGF-­‐β(87,	  88).	  In	  contrast,	  CD103-­‐	  LPDCs	  support	  the	  development	  of	  inflammation,	  and	  increase	  expression	  of	  inflammatory	  mediators	  such	  as	  TNFα	  and	  IL-­‐6	  following	  stimulation	  with	  TLR	  ligands(128).	  The	  presence	  of	  CD103+	  LPDC	  is	  particularly	  important	  in	  preventing	  unnecessary	  inflammation,	  as	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the	  absence	  of	  CD103+	  CX3CR1-­‐	  LPDCs	  enhances	  epithelial	  damage	  during	  colitis	  (129).	  
Innate	  Lymphoid	  Cells	  (ILCs)	  are	  another	  cellular	  population	  found	  in	  the	  lamina	  propria(130,	  131).	  ILCs	  morphologically	  resemble	  lymphocytes,	  but	  do	  not	  possess	  recombination	  activating	  gene-­‐dependent	  antigen	  receptors(132).	  ILCs	  can	  be	  broken	  down	  into	  three	  broad	  groups(132).	  The	  defining	  characteristic	  of	  group	  1	  ILCs,	  such	  as	  NK	  cells,	  is	  the	  production	  of	  IFNγ(132).	  Many	  group	  1	  ILCs	  are	  also	  T-­‐bet+(132,	  133),	  and	  group	  1	  ILCs	  can	  be	  found	  at	  sites	  of	  mucosal	  inflammation(133).	  In	  contrast,	  generation	  of	  group	  2	  ILCs	  requires	  GATA3	  and	  RORα(132),	  and	  IL-­‐5	  and	  IL-­‐13	  are	  the	  signature	  cytokines	  of	  this	  group(132).	  Group	  2	  ILCs	  are	  important	  in	  responding	  to	  nematode	  infections(132).	  Particularly	  relevant	  to	  the	  intestinal	  tract	  are	  group	  3	  ILCs,	  which	  are	  primarily	  defined	  by	  their	  ability	  to	  produce	  IL-­‐22	  and	  IL-­‐17(132).	  Additionally,	  the	  generation	  and	  activity	  of	  group	  3	  ILCs	  is	  dependent	  on	  RORγt(132).	  Recent	  evidence	  has	  strongly	  suggested	  that	  IL-­‐17	  positive	  group	  3	  ILCs	  drive	  colonic	  inflammation	  during	  Helicobacter	  hepaticus	  infection(131).	  In	  contrast,	  during	  
Citrobacter	  rodentium	  (C.	  rodentium)	  colitis	  group	  3	  ILCs	  are	  known	  to	  produce	  IL-­‐22(130).	  IL-­‐22	  drives	  antimicrobial	  peptide	  expression	  and	  is	  required	  to	  prevent	  severe	  intestinal	  pathology	  and	  mortality	  during	  C.	  rodentium	  colitis(134).	  Thus,	  group	  3	  ILCs	  are	  important	  intestinal	  sources	  of	  IL-­‐17	  and	  IL-­‐22,	  and	  can	  both	  promote	  and	  protect	  against	  intestinal	  pathology	  during	  insult(131,	  132,	  134).	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Innate	  Inflammation	  in	  the	  Large	  Bowel	  
	   The	  host	  response	  to	  a	  wide	  range	  of	  bacterial	  and	  chemical	  perturbations	  within	  the	  large	  intestine	  is	  characterized	  by	  conserved	  immunological	  phenomena.	  Inflammatory	  cytokines,	  including	  IL-­‐23,	  IFNγ,	  and	  TNFα	  are	  induced	  locally	  in	  response	  to	  the	  challenge(82,	  135-­‐137).	  Leukocyte	  recruiting	  chemokines,	  including	  CXCL1,	  CXCL2,	  and	  CCL2	  are	  also	  induced,	  and	  are	  associated	  with	  an	  influx	  of	  monocytes	  and	  neutrophils	  into	  the	  mucosa(78,	  80,	  82,	  135,	  138,	  139).	  Finally,	  intestinal	  histopathology	  characterized	  by	  epithelial	  damage	  and/or	  edema	  develops,	  as	  a	  result	  of	  either	  the	  perturbing	  agent	  directly	  or	  by	  the	  resulting	  immune	  response(49,	  72,	  80,	  134,	  138,	  140).	  	   Neutrophils,	  defined	  by	  high	  levels	  of	  Gr-­‐1	  (Ly6G)	  and	  CD11b	  expression,	  are	  myeloid	  cells	  that	  are	  rapidly	  recruited	  to	  the	  colonic	  epithelium	  during	  colitis(78,	  80,	  82,	  139).	  Neutrophil	  recruitment	  is	  often	  beneficial	  to	  the	  host,	  as	  neutrophils	  are	  capable	  of	  phagocytosing	  pathogens(141,	  142),	  and	  interference	  with	  neutrophil	  recruitment	  is	  associated	  with	  decreased	  host	  survival	  during	  acute	  large	  bowel	  infections(74,	  76,	  78,	  143).	  Neutrophils	  are	  also	  capable	  of	  supporting	  inflammatory	  responses	  directly	  by	  producing	  inflammatory	  cytokines	  directly	  including	  IL-­‐1β,	  TNFα,	  and	  IL-­‐8(141,	  144).	  However,	  neutrophil	  recruitment	  is	  commonly	  associated	  with	  the	  development	  of	  colonic	  histopathology(82,	  138),	  and	  neutrophil	  elastase	  is	  partially	  responsible	  for	  intestinal	  histopathology	  during	  DSS	  colitis(140).	  Thus,	  neutrophil	  recruitment	  can	  both	  reduce	  pathogen	  burden	  and	  protect	  against	  mortality	  as	  well	  as	  drive	  tissue	  damage	  during	  innate	  colitis.	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   IL-­23	  is	  a	  critical	  driver	  of	  the	  host	  response	  during	  acute	  inflammation	  at	  mucosal	  sites,	  including	  in	  the	  large	  bowel(135,	  138,	  145-­‐147).	  IL-­‐23	  promotes	  neutrophil	  recruitment	  during	  acute	  pulmonary	  inflammation(145-­‐147),	  and	  the	  recruitment	  of	  neutrophils	  is	  largely	  dependent	  on	  IL-­‐23	  in	  both	  infectious	  and	  chemically	  induced	  models	  of	  large	  bowel	  inflammation(135,	  138).	  The	  expression	  of	  the	  neutrophil	  chemotactic	  factor	  KC	  (CXCL1)	  is	  also	  driven	  by	  IL-­‐23	  during	  S.	  
typhimurium	  typhlocolitis(135).	  Additionally,	  expression	  of	  the	  antimicrobial	  peptide	  RegIIIγ	  is	  almost	  entirely	  dependent	  on	  IL-­‐23	  during	  S.	  typhimurium	  typhlocolitis	  as	  well	  as	  DSS	  colitis(135,	  138).	  	   IL-­22	  is	  a	  pleiotropic	  cytokine	  that	  is	  induced	  in	  response	  to	  mucosal	  inflammation,	  including	  innate	  colitis(80,	  82,	  135,	  138,	  148).	  The	  induction	  of	  IL-­‐22	  at	  mucosal	  sites	  is	  driven	  by	  IL-­‐23(134,	  135,	  138,	  146),	  and	  several	  studies	  have	  demonstrated	  an	  epithelial-­‐protective	  role	  for	  IL-­‐22	  during	  mucosal	  inflammation(134,	  149).	  IL-­‐22	  limits	  the	  severity	  of	  intestinal	  histopathology	  during	  infectious	  and	  chemically	  induced	  colitis(134,	  149).	  Furthermore,	  IL-­‐22	  both	  promotes	  RegIIIγ	  induction	  and	  limits	  mortality	  during	  C.	  rodentium	  colits(134).	  However,	  IL-­‐22	  also	  promotes	  neutrophil	  recruitment	  during	  chemically	  induced	  pulmonary	  inflammation(148),	  and	  stimulation	  of	  colonic	  epithelial	  cells	  and	  colonic	  subepithelial	  myofibroblasts	  with	  IL-­‐22	  results	  in	  the	  production	  of	  neutrophil	  chemotactic	  factors(150,	  151).	  As	  such,	  IL-­‐22	  can	  potentiate	  a	  wide	  array	  of	  host	  responses	  at	  mucosal	  sites.	  	  	   IL-­17	  is	  a	  proinflammatory	  cytokine	  that	  is	  commonly	  and	  rapidly	  induced	  at	  sites	  of	  mucosal	  inflammation(80,	  135,	  136,	  138,	  146,	  148).	  IL-­‐17	  promotes	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neutrophil	  recruitment	  in	  models	  of	  pulmonary	  inflammation	  including	  K.	  
pneumoniae	  infections(152)	  and	  bleomycin	  challenge(148),	  as	  well	  as	  intestinal	  inflammation	  models	  including	  S.	  typhimurium	  infection(153)	  and	  TNBS(154)	  and	  DSS(155)	  colitis.	  IL-­‐17	  also	  contributes	  to	  epithelial	  damage	  during	  colonic	  inflammation	  as	  well(154,	  155).	  Recent	  studies	  have	  demonstrated	  that	  IL-­‐23	  can	  drive	  the	  expression	  of	  IL-­‐17	  during	  mucosal	  inflammation(135,	  138).	  	   Previous	  studies	  have	  reported	  a	  role	  for	  TNFα 	  signaling	  in	  promoting	  myeloid	  cell	  recruitment	  during	  mucosal	  inflammation	  (156,	  157).	  TNFα	  can	  enhance	  the	  expression	  of	  CCL3	  during	  chemically-­‐induced	  pulmonary	  inflammation	  (157),	  and	  interference	  with	  TNFα	  signaling	  reduces	  neutrophil	  recruitment	  in	  response	  to	  acute	  allergic	  airway	  inflammation	  (156).	  TNFα	  can	  contribute	  to	  inflammatory	  cytokine	  expression	  and	  tissue	  damage	  during	  mucosal	  inflammation(158,	  159).	  Directly	  applicable	  to	  gastrointestinal	  inflammation,	  during	  2,4,6-­‐Trinitrobenzenesulfonic	  acid	  (TNBS)	  colitis,	  TNFα	  signaling	  promotes	  both	  IL-­‐18	  and	  TNFα	  expression	  as	  well	  as	  the	  development	  of	  intestinal	  histopathology	  (159).	  Furthermore,	  TNFα	  also	  protects	  against	  immunopathology	  in	  response	  to	  C.	  
rodentium	  colitis(137),	  highlighting	  the	  pleiotropic	  nature	  of	  TNFα	  signaling	  during	  mucosal	  inflammation.	  	  Likewise,	  GM-­CSF	  is	  a	  potent	  driver	  of	  mucosal	  inflammation	  in	  numerous	  settings,	  including	  the	  intestinal	  tract(160-­‐162).	  GM-­‐CSF	  can	  play	  a	  role	  in	  neutrophil	  recruitment	  during	  acute	  pulmonary	  inflammation	  (both	  chemical	  and	  microbial)(163-­‐166)	  and	  drive	  maximal	  production	  of	  TNFα	  and	  CXCL2	  in	  response	  to	  pulmonary	  LPS	  challenge(163).	  Colonic	  IL-­‐6	  production	  during	  chemically-­‐
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induced	  colitis	  has	  also	  been	  shown	  to	  be	  GM-­‐CSF-­‐dependent(167).	  However,	  GM-­‐CSF	  signaling	  also	  serves	  to	  protect	  the	  epithelium	  from	  damage	  during	  mucosal	  inflammation(167-­‐170).	  Ablation	  of	  GM-­‐CSF	  signaling	  can	  result	  in	  a	  significant	  increase	  in	  colonic	  histopathology,	  including	  colonic	  ulceration,	  during	  dextran	  sulfate	  sodium	  (DSS)-­‐induced	  colitis(167,	  169).	  Furthermore,	  treatment	  of	  afflicted	  animals	  with	  exogenous	  GM-­‐CSF	  is	  capable	  of	  reducing	  colonic	  ulceration	  in	  the	  same	  model(168).	  Thus,	  the	  host	  response	  to	  innate	  colitis	  is	  characterized	  by	  the	  induction	  of	  pleiotropic	  cytokines,	  capable	  of	  potentiating	  inflammatory	  responses	  such	  as	  neutrophil	  recruitment	  as	  well	  as	  epithelial	  protective	  responses(134).	  	  	  
	  
	  
Innate	  Inflammatory	  Responses	  to	  C.	  difficile	  TcdA	  and	  TcdB	  
	   Many	  studies	  have	  focused	  on	  the	  innate	  inflammatory	  responses	  of	  cultured	  myeloid	  cell	  populations	  to	  C.	  difficile	  TcdA	  and	  TcdB;	  the	  two	  best	  characterized	  virulence	  factors	  in	  C.	  difficile.	  Stimulation	  of	  human	  monocytes	  with	  TcdA	  or	  TcdB	  induces	  high	  levels	  of	  IL-­‐8	  production,	  and	  TcdA	  stimulation	  alone	  is	  sufficient	  to	  elicit	  significant	  production	  of	  both	  IL-­‐1β	  and	  TNFα(171).	  A	  more	  recent	  study	  has	  demonstrated	  that	  IL-­‐1β	  production	  in	  THP-­‐1	  monocyte-­‐like	  cells	  in	  response	  to	  TcdA	  and	  TcdB	  is	  associated	  with	  caspase	  1	  activation,	  and	  that	  IL-­‐1β	  production	  was	  drastically	  reduced	  in	  peritoneal	  macrophages	  isolated	  from	  ASC-­‐deficient	  mice(172).	  Dendritic	  cells	  also	  react	  rapidly	  to	  C.	  difficile	  stimulation:	  treatment	  of	  bone	  marrow	  derived	  immature	  dendritic	  cells	  with	  TcdA	  results	  in	  maturation,	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characterized	  by	  increased	  expression	  of	  CD80,	  CD86,	  and	  MHCII,	  within	  24	  hours	  of	  stimulation(173).	  Dendritic	  cells	  under	  these	  conditions	  also	  express	  high	  levels	  of	  CXCL2	  transcript	  within	  12	  hours	  of	  treatment	  with	  TcdA(173).	  Bone	  marrow	  derived	  dendritic	  cell	  maturation	  and	  activation	  can	  also	  be	  driven	  by	  stimulation	  with	  C.	  difficile	  surface	  layer	  proteins	  in	  a	  TLR4-­‐dependent	  manner(174).	  Additionally,	  mast	  cells	  release	  high	  levels	  of	  TNFα	  following	  treatment	  with	  TcdA(175).	  	  Though	  intoxication	  of	  intestinal	  epithelial	  cells	  with	  C.	  difficile	  toxins	  results	  in	  cell	  rounding	  and	  death(49,	  176,	  177),	  these	  cells	  also	  mount	  innate	  inflammatory	  responses	  following	  exposure	  to	  C.	  difficile	  toxins(176,	  178-­‐180).	  One	  of	  the	  most	  commonly	  reported	  responses	  of	  epithelial	  cells	  in	  vitro	  is	  increased	  expression	  of	  IL-­‐8,	  which	  has	  been	  reported	  from	  both	  colonocyte	  and	  goblet	  cell-­‐like	  cell	  lines(176,	  178,	  180).	  The	  secretion	  of	  these	  chemokines	  also	  appears	  to	  be	  directed,	  as	  treatment	  of	  polarized	  epithelial	  cells	  with	  TcdA	  in	  vitro	  results	  in	  primarily	  basolateral	  secretion	  of	  IL-­‐8(180).	  Furthermore,	  epithelial	  cells	  isolated	  from	  in	  vivo	  ileal	  loops	  injected	  with	  TcdA	  show	  increased	  expression	  of	  CXCL2(179).	  	  As	  mice	  are	  refractory	  to	  C.	  difficile	  colonization	  without	  antibiotic	  pretreatment(72),	  many	  early	  animal	  studies	  were	  performed	  by	  delivering	  purified	  
C.	  difficile	  toxins	  directly	  to	  the	  gastrointestinal	  tract(172,	  181-­‐183).	  in	  vitro	  experiments	  using	  excised	  rabbit	  ileum	  revealed	  that	  treatment	  with	  C.	  difficile	  toxins	  promotes	  intestinal	  fluid	  secretion(184).	  Treatment	  of	  intestinal	  epithelial	  cell	  monolayers	  in	  vitro	  with	  purified	  TcdA	  results	  in	  rapid	  loss	  of	  transepithelial	  resistance	  and	  enhances	  tight	  junction	  permeability(185),	  suggesting	  the	  fluid	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secretion	  seen	  in	  toxin-­‐treated	  animals	  was	  due	  to	  loss	  of	  epithelial	  integrity	  caused	  by	  TcdA	  intoxication.	  Subsequent	  studies	  utilizing	  ileal	  loops	  instilled	  with	  C.	  difficile	  toxin	  also	  demonstrated	  high	  levels	  of	  fluid	  secretion	  in	  response	  to	  toxins,	  as	  well	  as	  marked	  disruption	  of	  intestinal	  architecture	  and	  neutrophil	  recruitment	  (172,	  182,	  183,	  186,	  187).	  	  The	  ileal	  loop	  model	  has	  also	  been	  used	  to	  investigate	  the	  immunological	  drivers	  of	  inflammation	  in	  response	  to	  C.	  difficile	  toxins,	  especially	  those	  mechanisms	  underlying	  neutrophil	  recruitment(172,	  179,	  181,	  186,	  188).	  Studies	  using	  the	  ileal	  loop	  model	  reported	  decreased	  CXCL1	  expression	  and	  decreased	  MPO	  levels	  in	  the	  absence	  of	  IFNγ(188).	  The	  depletion	  of	  mast	  cells	  also	  impairs	  neutrophil	  recruitment	  in	  response	  to	  TcdA(187),	  as	  does	  the	  chemical	  inhibition	  p38	  MAP	  kinase	  activation(189).	  Rat	  ileum	  epithelial	  cells	  have	  also	  a	  cellular	  source	  of	  CXCL2	  following	  TcdA	  administration	  to	  the	  rat	  ileum(179).	  Furthermore,	  neutrophils	  have	  also	  been	  suggested	  to	  promote	  intestinal	  histopathology	  in	  response	  to	  C.	  difficile	  toxins,	  as	  interference	  with	  neutrophil	  recruitment	  using	  an	  anti-­‐CD18	  antibody	  is	  also	  associated	  with	  decreased	  fluid	  secretion	  and	  epithelial	  damage	  in	  the	  rabbit	  ileum(186).	  Finally,	  Ng	  and	  colleagues	  demonstrated	  that	  IL-­‐1β,	  IL-­‐18,	  and	  CXCL1	  production	  as	  well	  as	  intestinal	  histopathology,	  in	  the	  ileum	  in	  response	  to	  TcdA	  and	  TcdB	  was	  largely	  dependent	  upon	  the	  NLRP3	  inflammasome(172).	  Many	  of	  these	  results,	  including	  the	  requirement	  for	  NLRP3	  inflammasome	  activity	  for	  IL-­‐1β	  production	  and	  neutrophil	  recruitment	  (as	  assessed	  by	  MPO	  activity),	  were	  later	  confirmed	  in	  the	  colon	  by	  administering	  C.	  
difficile	  toxin	  intrarectally(181).	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Mouse	  Modeling	  of	  Clostridium	  difficile	  Colitis	  While	  the	  work	  by	  Hirota	  and	  colleagues	  and	  others	  demonstrate	  that	  toxin-­‐based	  models	  can	  provide	  mechanistic	  insight	  into	  the	  initial	  inflammatory	  response	  to	  C.	  difficile	  toxins(172,	  179,	  181,	  186,	  188),	  such	  models	  are	  not	  without	  limitations.	  In	  addition	  to	  potential	  differences	  in	  the	  host	  response	  to	  purified	  bacterial	  toxins	  as	  opposed	  to	  a	  metabolically	  active	  infectious	  organism,	  toxin	  based	  models	  often	  offer	  a	  very	  limited	  timeframe	  before	  which	  samples	  must	  be	  collected	  (often	  four	  hours	  or	  less)(172,	  179,	  181,	  188).	  	  In	  recent	  years	  numerous	  murine	  models	  of	  C.	  difficile	  infection,	  relying	  on	  antibiotic	  pretreatment	  to	  permit	  infection,	  have	  been	  developed.	  The	  first	  published	  model,	  developed	  by	  Chen	  at	  colleagues,	  relied	  on	  the	  administration	  of	  a	  cocktail	  of	  kanamycin,	  gentamicin,	  colistin,	  metronidazole,	  and	  vancomycin	  in	  the	  drinking	  water	  as	  well	  as	  a	  subsequent	  intraperitoneal	  injection	  of	  clindamycin	  to	  permit	  C.	  difficile	  colonization	  and	  infection(72).	  This	  particular	  model	  has	  been	  utilized	  in	  several	  studies	  to	  infect	  mice	  with	  C.	  difficile	  and	  investigate	  the	  host	  response	  to	  infection(66,	  77,	  82,	  190).	  Subsequent	  studies	  have	  utilized	  modified	  versions	  of	  the	  aforementioned	  protocol	  with	  the	  addition	  of	  ampicillin	  to	  the	  cocktail(74-­‐76),	  while	  other	  groups	  have	  developed	  models	  using	  solely	  intraperitoneal	  clindamycin	  injections(73,	  78),	  or	  the	  use	  of	  broad-­‐spectrum	  third-­‐generation	  cephalosporins	  in	  drinking	  water(59,	  79-­‐81,	  83,	  191,	  192)	  to	  permit	  C.	  
difficile	  colonization.	  	  Two	  strains	  of	  C.	  difficile,	  VPI	  10463	  and	  630,	  are	  commonly	  used	  in	  mouse	  models	  of	  C.	  difficile	  colitis(59,	  66,	  74-­‐76,	  78-­‐83).	  Both	  VPI	  10463(17,	  193)	  and	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630(21)	  contain	  the	  pathogenicity	  locus,	  which	  encodes	  genes	  for	  TcdA	  and	  TcdB	  production,	  release,	  and	  regulation(18).	  However,	  in	  vivo	  infection	  with	  C.	  difficile	  strain	  630	  is	  associated	  with	  less	  cytotoxicity	  (per	  gram	  of	  cecal	  content)	  than	  VPI	  10463	  infection(59).	  Consistently,	  630	  infection	  is	  associated	  with	  less	  mortality	  and	  less	  severe	  intestinal	  histopathology	  as	  compared	  to	  VPI	  10463	  infection(59).	  However,	  infection	  of	  susceptible	  animals	  with	  either	  strain	  results	  in	  a	  conserved	  host	  response	  characterized	  by	  inflammatory	  cell	  recruitment,	  the	  induction	  of	  inflammatory	  cytokines	  and	  chemokines,	  and	  the	  development	  of	  intestinal	  histopathology	  in	  the	  large	  bowel	  (59,	  66,	  74-­‐76,	  78-­‐82).	  Thus,	  while	  the	  overall	  severity	  of	  disease	  differs	  between	  the	  two	  strains	  of	  C.	  difficile,	  the	  host	  inflammatory	  responses	  to	  both	  strains	  are	  conserved,	  and	  infection	  with	  either	  strain	  serves	  as	  an	  appropriate	  context	  in	  which	  the	  investigate	  the	  mechanisms	  underlying	  inflammatory	  responses	  during	  C.	  difficile	  colitis.	  	  
	  
	  
The	  Host	  Response	  to	  Clostridium	  difficile	  Colitis	  in	  vivo	  Utilizing	  the	  mouse	  models	  mentioned	  above,	  numerous	  groups	  have	  begun	  to	  investigate	  the	  mechanisms	  underlying	  inflammation,	  microbial	  recognition,	  and	  immunopathology	  during	  C.	  difficile	  infection(74-­‐82,	  174,	  190,	  191,	  194).	  Initial	  studies,	  using	  vegetative	  C.	  difficile	  as	  the	  infectious	  challenge,	  reported	  marked	  myeloid	  cell	  recruitment	  to	  the	  large	  bowel(59,	  72,	  74,	  76,	  80,	  82,	  195).	  For	  example,	  Sadighi	  Akha	  and	  colleagues	  reported	  significant	  neutrophil	  recruitment	  to	  the	  colon	  in	  association	  with	  marked	  intestinal	  histopathology	  and	  increased	  expression	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of	  inflammatory	  cytokines	  including	  TNFα,	  GM-­‐CSF,	  and	  CXCL1(82).	  Subsequent	  studies	  inoculating	  with	  C.	  difficile	  spores	  likewise	  reported	  marked	  neutrophil	  recruitment	  to	  the	  large	  bowel	  associated	  with	  the	  activation	  of	  numerous	  inflammatory	  pathways(78,	  79,	  81,	  191,	  194).	  Collectively,	  these	  studies	  demonstrate	  that	  infection	  with	  viable	  C.	  difficile,	  either	  vegetative	  cells	  or	  C.	  difficile	  spores,	  results	  in	  a	  conserved	  host	  response	  highlighted	  by	  robust	  neutrophil	  recruitment,	  marked	  intestinal	  histopathology,	  and	  the	  induction	  of	  inflammatory	  cytokines	  and	  chemokines	  including	  CXCL1(59,	  72,	  74-­‐82,	  191,	  194).	  	  Recent	  studies	  have	  focused	  on	  the	  host	  signals	  required	  for	  full	  recruitment	  of	  neutrophils	  in	  response	  to	  infection(74-­‐76,	  78,	  79,	  81).	  For	  example,	  Hasegawa	  and	  colleagues	  demonstrated	  a	  key	  role	  for	  NOD1	  in	  supporting	  CXCL1	  expression	  and	  neutrophil	  recruitment	  to	  the	  large	  bowel	  following	  C.	  difficile	  infection(76).	  Furthermore,	  Jarchum	  and	  colleagues	  also	  reported	  decreased	  neutrophil	  recruitment	  and	  CXCL1	  expression	  in	  MyD88-­‐deficient	  mice(78).	  Additional	  studies	  have	  suggested	  roles	  for	  ASC(74)	  and	  the	  combined	  signaling	  of	  IL-­‐22	  and	  CD160(81)	  in	  driving	  neutrophil	  recruitment	  to	  the	  large	  intestine	  in	  response	  to	  C.	  
difficile	  infection.	  	  These	  investigations	  into	  the	  host	  mechanisms	  promoting	  neutrophil	  recruitment	  have	  also	  revealed	  an	  association	  between	  reduced	  neutrophil	  recruitment	  and	  increased	  mortality	  during	  C.	  difficile	  infection(74,	  76,	  78).	  For	  example,	  in	  the	  study	  mentioned	  above	  by	  Hasegawa	  et	  al,	  the	  deficiency	  in	  neutrophil	  recruitment	  seen	  in	  NOD1-­‐deficient	  mice	  was	  also	  associated	  with	  a	  significant	  increase	  in	  mortality	  following	  C.	  difficile	  challenge(76).	  Furthermore,	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elimination	  of	  neutrophils	  through	  the	  use	  of	  a	  depleting	  mAb	  was	  also	  associated	  with	  decreased	  survival(78),	  seeming	  to	  suggest	  a	  protective	  role	  for	  neutrophil	  recruitment	  in	  response	  to	  C.	  difficile	  infection.	  	  Other	  studies,	  however,	  have	  reported	  interventions	  that	  reduce	  neutrophil	  recruitment	  without	  increased	  mortality(79-­‐81).	  For	  example,	  Sadighi	  Akha	  and	  colleagues	  reported	  decreased	  CXCL1	  expression	  and	  reduced	  neutrophil	  recruitment	  following	  treatment	  with	  a	  combination	  of	  anti-­‐IL-­‐22	  and	  anti-­‐CD160	  mAb,	  without	  any	  increase	  in	  mortality(81).	  Additionally,	  while	  El-­‐Zaatari	  et	  al	  reported	  increased	  neutrophil	  recruitment	  in	  association	  with	  decreased	  C.	  difficile	  colonization	  in	  IDO-­‐deficient	  mice,	  the	  increase	  in	  neutrophil	  recruitment	  was	  also	  associated	  with	  more	  severe	  intestinal	  histopathology(191).	  Thus,	  the	  host	  inflammatory	  signals	  that	  drive	  neutrophil	  recruitment	  to	  the	  colon,	  as	  well	  as	  the	  role	  of	  neutrophils	  themselves	  in	  promoting	  inflammatory	  responses	  in	  the	  colon,	  in	  response	  to	  C.	  difficile	  infection	  is	  poorly	  understood.	  	  	  
Central	  Hypothesis:	  	  	  
C.	  difficile	  infection	  results	  in	  induction	  of	  interleukin-­23,	  interleukin-­17,	  and	  
interleukin-­22,	  which	  drives	  increased	  chemokine	  and	  inflammatory	  cytokine	  
production,	  neutrophil	  recruitment,	  and	  immunopathology	  in	  the	  colon	  
	  
Aims:	  
1. To	  determine	  the	  role	  of	  GM-­CSF	  in	  promoting	  neutrophil	  recruitment	  
and	  inflammatory	  cytokine	  expression	  during	  acute	  C.	  difficile	  colitis.	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Induction	  of	  GM-­‐CSF	  in	  response	  to	  C.	  difficile	  infection	  has	  been	  previously	  reported(79,	  82),	  and	  GM-­‐CSF	  is	  known	  to	  promote	  neutrophil	  recruitment	  and	  inflammatory	  cytokine	  expression	  during	  inflammation	  at	  numerous	  mucosal	  sites(160-­‐167).	  However,	  the	  role	  of	  GM-­‐CSF	  is	  driving	  neutrophil	  recruitment	  and	  the	  induction	  of	  inflammatory	  cytokines	  during	  C.	  difficile	  infection	  has	  never	  been	  directly	  investigated.	  	  
2. To	  determine	  the	  role	  of	  neutrophils	  in	  driving	  intestinal	  
histopathology	  and	  inflammatory	  cytokine	  expression,	  and	  the	  role	  of	  
TNFα 	  in	  promoting	  neutrophil	  recruitment	  and	  inflammatory	  cytokine	  
expression,	  in	  response	  to	  C.	  difficile	  infection.	  Neutrophil	  recruitment,	  in	  association	  with	  inflammatory	  cytokine	  expression	  including	  TNFα,	  is	  one	  of	  the	  most	  prominent	  host	  responses	  to	  C.	  difficile	  infection(74,	  76,	  78-­‐82,	  191).	  Neutrophils	  are	  known	  to	  produce	  inflammatory	  cytokines(141,	  144)	  and	  their	  recruitment	  is	  often	  associated	  with	  host	  tissue	  damage	  during	  inflammation(82,	  138,	  140).	  However,	  the	  role	  of	  neutrophils	  in	  driving	  epithelial	  damage	  and	  inflammatory	  cytokine	  expression	  has	  not	  been	  extensively	  studied.	  Additionally,	  TNFα	  promotes	  neutrophil	  recruitment	  in	  numerous	  models	  of	  mucosal	  inflammation(156,	  157),	  and	  is	  induced	  in	  response	  to	  
C.	  difficile	  infection(80,	  82),	  yet	  the	  role	  of	  TNFα	  in	  supporting	  neutrophil	  recruitment	  and	  inflammatory	  cytokine	  expression	  during	  C.	  difficile	  colitis	  is	  unknown.	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3. To	  determine	  the	  roles	  of	  IL-­23,	  IL-­22,	  and	  IL-­17a	  in	  driving	  CXC	  
chemokine	  expression	  and	  neutrophil	  recruitment	  during	  C.	  difficile	  
colitis.	  	  IL-­‐23	  promotes	  neutrophil	  recruitment	  and	  neutrophil-­‐recruiting	  chemokine	  expression	  in	  numerous	  models	  of	  mucosal	  inflammation	  in	  both	  the	  lungs	  and	  the	  intestinal	  tract(135,	  138,	  145-­‐147).	  Furthermore,	  IL-­‐23	  controls	  the	  expression	  of	  both	  IL-­‐22	  and	  IL-­‐17a,	  two	  cytokines	  capable	  of	  controlling	  neutrophil	  recruitment(148,	  150-­‐154),	  during	  inflammation	  at	  mucosal	  sites(134,	  135,	  138).	  Though	  a	  recent	  study	  has	  suggested	  a	  role	  for	  IL-­‐23	  in	  driving	  morbidity	  and	  mortality	  during	  C.	  difficile	  infection(190),	  the	  role	  of	  IL-­‐23	  in	  promoting	  neutrophil	  influx	  during	  C.	  difficile	  colitis	  has	  not	  been	  explicitly	  examined.	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Chapter	  2	  	  
Materials	  and	  Methods	  
	  
Animals	  and	  Housing:	  	  Male	  C57BL/6,	  mice	  aged	  5-­‐11	  weeks	  were	  used	  in	  all	  studies.	  All	  mice	  were	  either	  obtained	  directly	  from	  Jackson	  labs,	  or	  acquired	  from	  a	  breeding	  colony	  maintained	  at	  the	  University	  of	  Michigan	  founded	  by	  Jackson	  breeders.	  	  
Chapter	  5:	  Male	  and	  female	  IL-­‐17-­‐/-­‐	  (IL-­‐17KO)	  and	  p19-­‐/-­‐	  (IL-­‐23KO)	  mice	  aged	  5-­‐14	  weeks	  were	  used	  as	  well.	  IL-­‐17KO	  and	  IL-­‐23KO	  mice	  on	  a	  C57BL/6	  background	  were	  likewise	  obtained	  from	  breeding	  colonies	  maintained	  at	  the	  University	  of	  Michigan.	  IL-­‐23KO	  breeders	  were	  a	  kind	  gift	  from	  Dr.	  Benjamin	  Segal,	  University	  of	  Michigan.	  	  All	  mice	  were	  maintained	  under	  specific	  pathogen-­‐free	  conditions,	  and	  autoclaved	  food,	  water,	  and	  bedding	  was	  provided	  ad	  libitum.	  All	  animal	  manipulations	  were	  carried	  out	  in	  laminar	  flow	  hood.	  All	  experiments	  were	  conducted	  in	  accordance	  with	  a	  protocol	  approved	  by	  the	  University	  Committee	  on	  Use	  and	  Care	  of	  Animals	  (UCUCA)	  at	  the	  University	  of	  Michigan.	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Clostridium	  difficile	  Spore	  Preparation:	  	  
C.	  difficile	  spore	  stocks,	  both	  VPI	  10463	  and	  630,	  were	  generated	  by	  plating	  an	  earlier	  spore	  preparation	  on	  Taurocholate	  Cefoxitin	  Cycloserine	  Fructose	  Agar	  (TCCFA)	  plates	  anaerobically.	  Single	  colonies	  were	  isolated,	  and	  grown	  overnight	  in	  Columbia	  broth.	  2ml	  of	  the	  overnight	  culture	  was	  inoculated	  into	  40ml	  of	  Clospore	  broth(1),	  and	  the	  culture	  was	  allowed	  to	  grow	  for	  seven	  days.	  Spores	  were	  collected	  by	  centrifugation,	  and	  washed	  to	  remove	  vegetative	  cell	  debris.	  All	  spore	  stocks	  were	  stored	  in	  water	  at	  40C	  until	  used.	  	  	  
Clostridium	  difficile	  Vegetative	  Cell	  Preparation:	  	   C.	  difficile	  was	  prepared	  for	  infection	  as	  described	  previously(2,	  3).	  Briefly,	  an	  overnight	  culture	  of	  C.	  difficile	  strain	  VPI	  10463	  (ATCC	  43255)	  was	  back-­‐diluted	  1:10	  in	  fresh	  brain-­‐heart	  infusion	  (BHIS)	  broth	  and	  grown	  for	  4-­‐6	  hours.	  The	  culture	  was	  then	  collected,	  washed	  in	  deoxygenated	  PBS	  (x3),	  and	  diluted	  to	  the	  desired	  dose.	  Mice	  were	  challenged	  via	  oral	  gavage.	  The	  inoculum	  was	  serially	  diluted	  and	  plated	  on	  BHIS	  plates	  to	  confirm	  dosage.	  C.	  difficile	  was	  grown	  and	  prepared	  for	  gavage	  in	  a	  Coy	  anaerobic	  chamber	  (Coy	  Industries).	  	  
Clostridium	  difficile	  Infection	  
	   Chapter	  3:	  Mice	  were	  treated	  with	  cefoperazone	  (0.5g/L)	  in	  their	  drinking	  water	  for	  five	  days	  in	  order	  to	  permit	  C.	  difficile	  infection.	  Following	  a	  2-­‐day	  recovery	  period,	  animals	  were	  challenged	  with	  4.73±0.59	  log10	  630	  spores	  as	  described	  previously(2).	  Following	  challenge,	  the	  inoculum	  was	  serially	  diluted	  and	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plated	  on	  Taurocholate	  Cefoxitin	  Cycloserine	  Fructose	  Agar	  (TCCFA)	  plates	  anaerobically	  in	  order	  to	  confirm	  the	  dosage.	  All	  animals	  were	  monitored	  for	  weight	  change	  during	  the	  course	  of	  the	  experiment,	  and	  were	  monitored	  for	  signs	  of	  severe	  
C.	  difficile	  infection	  (lethargy,	  hunched	  posture,	  >20%	  weight	  loss)	  and	  were	  euthanized	  if	  meeting	  any	  of	  these	  criteria.	  Uninfected	  animals	  received	  neither	  antibiotic	  treatment,	  nor	  C.	  difficile	  challenge.	  Samples	  were	  collected	  at	  four	  days	  post-­‐infection.	  	   Chapter	  4:	  For	  ceftriaxone	  and	  C.	  difficile	  infection	  studies,	  mice	  were	  treated	  with	  ceftriaxone	  (0.5g/L)	  (Sigma)	  given	  ad	  libitum	  in	  their	  drinking	  water	  for	  4	  days.	  Antibiotic	  water	  was	  replaced	  every	  other	  day.	  Mice	  were	  then	  given	  a	  two-­‐day	  recovery	  period	  on	  drinking	  water	  without	  antibiotic	  prior	  to	  infection	  with	  C.	  difficile	  as	  described	  previously(2,	  3).	  Ceftriaxone	  treated	  mice	  were	  given	  the	  antibiotic	  regimen	  only,	  and	  untreated	  animals	  were	  not	  manipulated	  at	  all.	  	  For	  C.	  difficile	  infection	  studies,	  mice	  received	  5.06	  ±	  0.31	  Log10	  CFU	  vegetative	  C.	  difficile	  via	  oral	  gavage	  on.	  C.	  difficile-­‐infected	  animals	  were	  monitored	  for	  signs	  of	  severe	  disease	  (hunched	  posture,	  lethargy,	  weight	  loss	  exceeding	  20%	  of	  baseline	  body	  weight)	  and	  were	  humanely	  euthanized	  if	  moribund.	  All	  surviving	  animals	  were	  euthanized	  two	  days	  post	  infection	  for	  subsequent	  analysis.	  
Chapter	  5:	  Mice	  were	  given	  a	  5	  day	  course	  of	  cefoperazone	  (0.5g/L)	  in	  their	  drinking	  water	  in	  order	  to	  permit	  C.	  difficile	  infection	  as	  described	  previously(2,	  4).	  After	  a	  two-­‐day	  recovery	  period,	  mice	  were	  challenged	  with	  5.70±0.25log10	  C.	  
difficile	  spores	  from	  strain	  VPI	  10463.	  Animals	  were	  followed	  for	  an	  additional	  two	  days,	  and	  all	  samples	  were	  collected	  at	  two	  days	  post	  infection.	  Inoculum	  dosage	  
	  	  44	  
was	  confirmed	  by	  serially	  diluting	  and	  plating	  the	  inoculum	  on	  TCCFA	  plates	  anaerobically.	  Animals	  were	  monitored	  following	  infection	  for	  signs	  of	  severe	  disease,	  including	  lethargy,	  hunched	  posture,	  >20%	  weight	  loss,	  and	  any	  animals	  found	  moribund	  were	  humanely	  euthanized.	  Untreated	  animals	  did	  not	  receive	  antibiotics	  or	  C.	  difficile	  challenge.	  	  	  
Neutralizing	  Antibody	  Treatments:	  
Chapter	  3	  Anti-­‐GM-­‐CSF	  Treatment:	  Animals	  were	  given	  three	  intraperitoneal	  injections	  of	  anti-­‐GM-­‐CSF	  mAb	  (clone	  MP1-­‐22E9).	  Each	  mouse	  received	  250μg	  per	  injection,	  and	  injections	  were	  given	  every	  48	  hours	  beginning	  24	  hours	  prior	  to	  infection(5,	  6).	  
Chapter	  4	  Anti-­‐Gr-­‐1	  and	  anti-­‐TNFα	  Treatment:	  Mice	  were	  given	  intraperitoneal	  injections	  of	  250µg	  of	  anti-­‐TNFα	  mAb	  (clone	  MP6-­‐XT3)	  one	  day	  prior	  to	  infection	  with	  C.	  difficile	  or	  injections	  of	  250µg	  of	  anti-­‐Gr-­‐1	  mAb	  (clone	  RB6-­‐8C5)	  one-­‐day	  prior	  and	  one-­‐day	  post	  infection.	  Mouse	  serum	  (Sigma)	  injections	  were	  administered	  to	  control	  mice.	  	  
Chapter	  5	  Anti-­‐IL-­‐22	  Treatment:	  Animals	  were	  given	  two	  intraperitoneal	  injections	  of	  anti-­‐IL-­‐22	  mAb	  (clone	  8E11).	  Each	  mouse	  received	  150µg	  antibody	  one	  day	  prior	  and	  one	  day	  post	  infection(7).	  The	  anti-­‐IL-­‐22	  mAB	  was	  a	  kind	  gift	  from	  Dr.	  Wenjun	  Ouyang(7).	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Histology:	  	  Colonic	  tissue	  was	  fixed	  in	  10%	  formalin	  for	  at	  least	  24	  hours,	  and	  then	  transferred	  to	  70%	  ethanol.	  Tissue	  was	  processed,	  paraffin	  embedded,	  sectioned,	  and	  used	  to	  prepare	  haematoxylin	  and	  eosin	  stained	  slides	  by	  McClinchey	  Histology	  Labs	  Inc.	  Representative	  images	  were	  acquired	  using	  an	  Olympus	  BX40	  light	  microscope	  (Olympus	  Corporation)	  and	  a	  QImaging	  MicroPublisher	  RTV	  5.0	  5	  megapixel	  camera.	  All	  images	  were	  acquired	  at	  a	  total	  magnification	  of	  400X.	  Panels	  were	  assembled	  in	  Adobe	  Photoshop	  CS5,	  version	  12.0.	  Image	  processing	  was	  restricted	  to	  global	  adjustments	  of	  brightness,	  contrast,	  and	  image	  size.	  	  	  
Histological	  Scoring:	  	  
	   Chapter	  4:	  Histological	  sections	  were	  coded,	  randomized,	  and	  scored	  in	  a	  blinded	  manner.	  The	  slides	  were	  first	  scored	  categorically	  on	  a	  0-­‐5	  scale	  for	  epithelium	  damage	  and	  for	  inflammation,	  using	  defined	  criteria.	  	  Epithelium	  damage	  was	  scored	  as	  follows:	  	  0,	  intact	  epithelium;	  1,	  minimal,	  scattered	  goblet	  cell	  loss	  with	  no	  significant	  epithelium	  destruction	  and	  no	  histologically	  defined	  loss	  of	  surface	  integrity;	  2,	  widespread	  moderate	  goblet	  cell	  loss	  with	  no	  significant	  epithelium	  destruction	  and	  no	  histologically	  defined	  loss	  of	  surface	  integrity;	  3,	  moderate	  to	  extensive	  widespread	  goblet	  cell	  loss	  with	  scattered	  epithelium	  destruction	  and	  histologically	  defined	  loss	  of	  surface	  integrity;	  4,	  extensive	  epithelium	  and	  goblet	  cell	  destruction	  with	  histologically	  defined	  loss	  of	  surface	  integrity;	  5,	  severe	  epithelium	  destruction	  and	  goblet	  cell	  destruction	  with	  widespread	  histologically	  apparent	  loss	  of	  surface	  integrity.	  Inflammation	  was	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scored	  as	  follows:	  0,	  no	  inflammation;	  1,	  minimal	  multifocal	  leukocytic	  infiltrates;	  2,	  moderate	  multifocal	  leukocytic	  infiltrates	  and	  low	  level	  edema	  (greater	  submucosal	  involvement);	  3,	  significant	  multifocal	  leukocytic	  infiltrates,	  edema,	  submucosal	  involvement;	  4,	  extensive	  multifocal	  leukocytic	  infiltrates,	  edema,	  extensive	  submucosal	  involvement;	  5,	  severe	  multifocal	  leukocytic	  infiltrates,	  extensive	  edema	  and	  submucosal	  involvement	  with	  luminal	  involvement	  and/or	  abscess	  formation.	  The	  slides	  were	  then	  assigned	  an	  overall	  score	  using	  a	  rank-­‐order	  scoring	  system.	  The	  total	  of	  both	  categorical	  scores	  (epithelium	  damage	  and	  inflammation)	  were	  used	  to	  rank	  all	  the	  slides	  in	  the	  study	  in	  order	  of	  increasing	  severity	  of	  histopathological	  changes	  (1=least,	  16=most).	  This	  method	  offers	  significant	  advantages	  over	  straight	  categorical	  scoring	  systems	  for	  comparing	  histological	  changes	  between	  groups	  and	  has	  been	  previously	  reported	  for	  scoring	  C.	  difficile-­‐induced	  intestinal	  pathology(2,	  8,	  9).	  
Chapter	  5:	  Light	  microscopic	  evaluation	  of	  H&E	  stained	  colonic	  sections	  was	  performed	  by	  a	  board-­‐certified	  veterinary	  pathologist	  (ILB).	  The	  pathologist	  was	  blinded	  to	  experimental	  groupings	  at	  the	  time	  of	  the	  evaluation,	  and	  sections	  were	  scored	  using	  a	  previously	  established	  system(2).	  Edema:	  0	  no	  edema,	  1	  mild,	  focal	  or	  multifocal	  edema	  with	  minimal	  submucosal	  expansion	  (<2X),	  2	  moderate	  multifocal	  edema	  with	  moderate	  submucosal	  expansion	  (2-­‐3X),	  3	  severe	  multifocal	  to	  coalescing	  edema	  with	  severe	  submucosal	  expansion	  (>3X),	  4	  same	  as	  3	  with	  diffuse	  submucosal	  expansion.	  Inflammation:	  0	  no	  inflammation,	  1	  minimal,	  multifocal	  neutrophilic	  infiltration,	  2	  moderate,	  multifocal	  neutrophilic	  infiltration	  (greater	  submucosal	  involvement),	  3	  severe	  multifocal	  to	  coalescing	  neutrophilic	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infiltration	  (greater	  submucosal	  +/-­‐	  mural	  involvement),	  4	  same	  as	  3	  with	  abscesses	  or	  extensive	  transmural	  involvement.	  Epithelial	  damage:	  0	  no	  epithelial	  damage,	  1	  mild	  multifocal,	  superficial	  damage	  (vacuolation,	  increased	  apoptosis,	  villus	  tip	  attenuation/necrosis),	  2	  moderate,	  multifocal	  superficial	  damage	  (same	  qualitative	  changes	  as	  above),	  3	  severe	  multifocal	  to	  coalescing	  mucosal	  damage	  +/-­‐	  pseudomembrane	  formation	  (intraluminal	  aggregate	  of	  neutrophils	  and	  sloughed	  epithelium	  in	  a	  fibrinous	  matrix	  covering	  eroded	  or	  ulcerated	  mucosa),	  4	  same	  as	  3	  with	  extensive	  pseudomembrane	  or	  ulcer	  formation.	  	  
Quantification	  of	  C.	  difficile	  colonization	  Mucosal	  C.	  difficile	  colonization	  was	  determined	  using	  a	  species-­‐specific	  qPCR	  of	  DNA	  isolated	  from	  colonic	  tissue.	  The	  C.	  difficile-­‐specific	  qPCR	  was	  performed	  as	  described	  previously(3,	  10).	  All	  reactions	  were	  carried	  out	  in	  a	  total	  volume	  of	  10µl.	  Each	  reaction	  contained	  2µl	  of	  template	  primers,	  6.25pmol	  forward	  and	  reverse	  tcdB	  primers,	  and	  1pmol	  tcdB	  probe.	  The	  cycling	  conditions	  and	  probe	  and	  primer	  sequences	  are	  identical	  to	  those	  used	  previously(3).	  Raw	  Ct	  values	  were	  normalized	  to	  signal	  from	  a	  single-­‐copy	  host	  internal	  control	  gene	  to	  generate	  dCt	  values(3,	  11).	  dCt	  values	  were	  then	  converted	  to	  “C.	  difficile	  genomes/g	  tissue”	  using	  a	  standard	  curve	  generated	  with	  known	  amounts	  of	  vegetative	  C.	  difficile	  and	  colonic	  tissue(4,	  12).	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Microbiome	  Analysis	  
	   Chapter	  3:	  The	  DNeasy	  blood	  and	  tissue	  kit	  (Qiagen,	  Valencia,	  CA)	  was	  used	  to	  extract	  genomic	  DNA	  from	  colonic	  tissue	  samples.	  The	  extraction	  was	  performed	  according	  to	  the	  manufacturer’s	  instructions	  except	  for	  the	  following	  modifications:	  adding	   a	   bead-­‐beating	   step	   using	   UltraClean	   fecal	   DNA	   bead	   tubes	   (Mo	   Bio	  Laboratories,	  Carlsbad,	  CA);	  doubling	  the	  amount	  of	  ATL	  buffer	  and	  the	  proteinase	  K	  used	   in	   the	   protocol;	   and	   decreasing	   by	   half	   the	   amount	   of	   the	  AE	   buffer	   used	   to	  elute	   the	  DNA.	  Subsequently,	   the	  V3,	  V4	  and	  V5	  hyper-­‐variable	   regions	  of	   the	  16S	  ribosomal	  RNA	  gene	  in	  each	  of	  the	  samples	  were	  targeted	  for	  amplification	  with	  the	  357F	   and	   929R	   primer	   sets(13).	   Amplicons	   were	   purified	   with	   the	   Agencourt	  AMPure	   XP	   PCR	   purification	   system	   (Beckman	   Coulter,	   Indianapolis,	   IN),	   and	  quantified	  with	  the	  Quant-­‐iT	  PicoGreen	  dsDNA	  kit	  (Life	  Technologies,	  Grand	  Island,	  NY)	   to	   obtain	   an	   equal	   pool	   for	   pyrosequencing.	   They	  were	   then	   sequenced	   on	   a	  Roche	   454	   GS	   Junior	   Titanium	   platform	   according	   to	   the	   manufacturer’s	  specifications.	   Bacterial	   16S	   sequences	   were	   first	   processed	   using	   the	   microbial	  ecology	  software	  suite	  mothur(14)	  to	  generate	  operational	  taxonomic	  units	  (OTUs)	  at	   a	   3%,	   i.e.	   species	   level	   of	   difference.	   These	  data,	   in	   the	   form	  of	   the	   .shared	   file,	  were	   then	   imported	   into	   the	  R	   software	   and	  analyzed	  using	   the	  R-­‐package	  vegan.	  The	  inverse	  Simpson	  diversity	  measure	  was	  calculated	  using	  the	  function	  diversity().	  	  
	   Chapter	   4:	   All	   procedures	   and	   analyses	   were	   performed	   as	   previously	  described(15).	  Briefly,	  DNA	  was	  isolated	  from	  rinsed	  colonic	  tissue	  and	  V3-­‐V5	  16S	  ribosomal	  RNA	  gene	  amplicon	  libraries	  generated.	  They	  were	  then	  sequenced	  on	  a	  Roche	   454	   GS	   Junior	   Titanium	   platform	   according	   to	   the	   manufacturer’s	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specifications.	   Bacterial	   16S	   rRNA	   gene	   sequences	   were	   processed	   using	   the	  microbial	   ecology	   software	   suite	   mothur(14)	   to	   generate	   operational	   taxonomic	  units	   (OTUs)	  at	  a	  3%	   level	  of	  difference	   (approximating	  species-­‐level	  differences).	  These	  data	  were	  then	  imported	  into	  the	  software	  package	  R	  and	  analyzed	  using	  the	  R	  add	  on-­‐package	  vegan(16).	  Rank	  abundance	  plots	  were	  generated	  by	  selecting	  for	  the	  OTUs	  that	  contributed	  to	  >0.5%	  of	  the	  population.	  The	  content	  of	  each	  treated	  tissue	  was	  ordered	  according	  to	  the	  average	  rank	  order	  of	  its	  untreated	  counterpart.	  Taxonomic	  classification	  of	  an	  OTU	  was	  assigned	  within	  mothur	  by	   identifying	   the	  consensus	  sequence	  of	  the	  OTU	  and	  assigning	  taxonomy	  using	  a	  Bayesian	  classifier	  trained	  on	  an	  RDP	  training	  set	  (classify.otu).	  
	  
RNA	  Isolation	  and	  Expression	  Analysis:	  	  Colonic	  tissue	  snips	  (1cm2)	  were	  collected	  from	  the	  center	  of	  the	  colon	  and	  stored	  in	  RNAlater	  (Ambion).	  RNA	  isolation	  and	  purification	  from	  colonic	  tissue	  was	  performed	  as	  described	  previously(4,	  12,	  15,	  17).	  Tissue	  was	  homogenized	  in	  TRIzol	  reagent	  (Life	  Technologies)	  and	  the	  resulting	  RNA	  was	  purified	  using	  the	  RNeasy	  Mini	  kit	  (Qiagen)	  according	  to	  the	  manufacturer’s	  instructions.	  The	  concentration	  of	  the	  purified	  RNA	  was	  determined	  using	  a	  Nanodrop	  instrument	  (Thermo	  Fisher).	  cDNA	  synthesis,	  using	  the	  purified	  RNA	  as	  a	  template,	  was	  performed	  using	  the	  RT2	  First	  Strand	  kit	  (Qiagen),	  and	  colonic	  gene	  expression	  was	  assessed	  using	  RT2	  Profiler	  PCR	  arrays	  (Qiagen).	  All	  reactions	  were	  run	  on	  a	  Roche	  Lightcycler	  480.	  In	  order	  to	  correct	  for	  variation	  between	  RT2	  Profiler	  PCR	  arrays,	  cross	  card	  normalization	  was	  performed	  as	  described	  previously(15,	  18).	  ΔCt	  (dCt)	  values	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were	  calculated	  by	  subtracting	  the	  geometric	  mean	  of	  two	  internal	  control	  genes	  from	  the	  Ct	  value	  of	  the	  gene	  of	  interest.(19)	  The	  2-­‐ddCt	  method	  was	  utilized	  to	  calculate	  fold	  change	  gene	  expression	  in	  treatment	  groups	  as	  compared	  to	  untreated	  animals	  for	  all	  comparisons(11).	  	  	  
Leukocyte	  Isolation:	  	  Leukocytes	  were	  isolated	  from	  colonic	  tissue	  as	  described	  previously(12).	  Isolated	  colonic	  tissue	  was	  minced	  with	  serrated	  scissors	  to	  physically	  disrupt	  the	  tissue,	  and	  was	  subsequently	  incubated	  in	  20ml	  Hank’s	  Balanced	  Salt	  Solution	  (HBSS)	  supplemented	  with	  2.5%	  fetal	  bovine	  serum,	  5mM	  EDTA,	  and	  1	  mM	  DTT	  for	  20	  minutes	  at	  370C.	  Tissue	  was	  then	  incubated	  in	  20ml	  of	  a	  digest	  solution	  consisting	  of	  HBSS	  supplemented	  with	  2.5%	  fetal	  bovine	  serum,	  400U/ml	  collagenase	  type	  3	  (Worthington	  Biochemical)	  and	  0.5mg/ml	  DNAse	  I	  (Roche)	  for	  60	  minutes	  at	  370C.	  Samples	  were	  then	  resuspended	  in	  20%	  Percoll	  (Sigma)	  in	  PBS,	  and	  centrifuged	  at	  900f	  for	  30	  minutes	  at	  room	  temperature	  without	  brake.	  The	  resulting	  single	  cell	  suspensions	  were	  stained	  for	  flow	  cytometric	  analysis.	  	  	  
Flow	  Staining	  and	  Analysis:	  	  Single	  cell	  suspensions	  were	  plated	  at	  a	  concentration	  of	  approximately	  106	  cells	  per	  well	  in	  a	  96	  well	  plate.	  Cells	  were	  blocked	  with	  unlabeled	  FC	  RIII/II,	  and	  then	  stained	  fluorescently	  labeled	  antibodies	  for	  30	  minutes.	  Cells	  were	  washed	  to	  remove	  excess	  antibody,	  and	  were	  resuspended	  in	  stabilizing	  fixative	  (BD	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Biosciences).	  Data	  was	  collected	  on	  a	  three-­‐laser	  Canto	  II	  using	  FACSDiva	  software	  (BD	  biosciences).	  All	  data	  analysis	  was	  performed	  in	  FlowJo	  (Treestar).	  	  
Chapter	  4:	  The	  following	  antibodies	  were	  used	  for	  flow	  cytometric	  analysis	  of	  intestinal	  leukocytes.	  CD11c	  (clone	  HL3),	  CD45	  (clone	  30-­‐F11),	  CD11b	  (clone	  M1/70),	  Gr-­‐1	  (clone	  RB6-­‐8C5),	  and	  Ly6C	  (clone	  AL-­‐21)	  as	  well	  as	  Fc	  RIII/II	  (clone	  2.4G2).	  All	  antibodies	  were	  purchased	  from	  BD	  Biosciences	  (San	  Diego,	  CA)	  and	  Biolegend	  (San	  Diego,	  CA).	  
Chapter	  5:	  Isolated	  colonic	  cells	  were	  stained	  with	  the	  following	  antibodies:	  CD45	  (clone	  30-­‐F11),	  CD11b	  (clone	  M1/70)	  and	  Ly6G	  (clone	  IA8)	  as	  well	  as	  Fc	  RIII/II	  (clone	  2.4G2).	  All	  antibodies	  were	  purchased	  from	  eBioscience,	  BD	  Pharmingen,	  and	  Biolegend.	  	  Total	  number	  of	  neutrophils	  per	  colon	  was	  calculated	  by	  multiplying	  the	  frequency	  of	  CD45High	  CD11bHigh	  Ly6GHigh	  neutrophils	  as	  defined	  by	  flow	  cytometry	  by	  the	  total	  number	  of	  cells	  in	  the	  colon	  in	  question.	  	  
Statistical	  Analysis:	  	  
Chapter	  3:	  For	  the	  initial	  assessment	  of	  GM-­‐CSF	  expression	  during	  C.	  difficile	  colitis,	   statistical	   significance	   was	   determined	   via	   an	   unpaired	   two-­‐tailed	   t-­‐test	  comparing	   dCt	   values	   from	   uninfected	   and	   C.	   difficile	   infected	  mice.	   For	   all	   other	  analyses	  of	  colonic	  gene	  expression,	  datasets	  were	  first	  checked	  by	  outlier	  analysis	  and	   then	   statistically	   significant	   changes	  were	   identified	  using	   a	  One-­‐Way	  ANOVA	  with	   a	   Tukey	   post	   hoc	   test	   comparing	   normalized	   dCt	   values	   from	   uninfected,	   C.	  
difficile	   infected,	   and	   anti-­‐GM-­‐CSF	   treated	   and	   C.	   difficile	   infected	   animals.	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Statistically	  significant	  changes	  in	  the	  Inverse	  Simpson	  Index	  were	  also	  determined	  using	  One-­‐Way	  ANOVA	  with	  a	  Tukey	  post	  hoc	  test.	  Significance	  was	  set	  at	  p<0.05	  in	  all	  analyses.	  
Chapter	  4:	  Unpaired	  two-­‐tailed	  t-­‐tests	  were	  used	  to	  identify	  statistically	  significant	  differences	  in	  gene	  expression	  between	  untreated	  and	  ceftriaxone-­‐treated	  mice.	  For	  all	  other	  analyses,	  statistically	  significant	  changes	  were	  identified	  using	  a	  One-­‐Way	  ANOVA	  with	  Tukey’s	  post	  hoc	  test	  for	  multiple	  comparisons.	  For	  all	  qPCR	  data	  (colonic	  gene	  expression	  and	  C.	  difficile	  colonization),	  statistical	  analysis	  was	  performed	  on	  normalized	  dCt	  values.	  Significance	  was	  set	  at	  p≤0.05	  in	  all	  analyses.	  
Chapter	  5:	  Statistically	  significant	  differences	  in	  gene	  expression	  were	  determined	  using	  a	  One-­‐Way	  ANOVA	  with	  Tukey’s	  post	  hoc	  test	  for	  multiple	  comparisons.	  For	  all	  qPCR	  data,	  statistical	  tests	  were	  performed	  on	  normalize	  dCt	  values(4,	  12).	  A	  One-­‐Way	  ANOVA	  with	  Tukey’s	  post	  hoc	  test	  was	  also	  used	  to	  identify	  significant	  differences	  in	  the	  number	  of	  neutrophils	  per	  colon.	  Significant	  differences	  in	  histopathological	  scoring	  were	  determined	  using	  the	  Kruskal-­‐Wallis	  test	  with	  followed	  by	  Dunn’s	  multiple	  comparisons	  test.	  For	  all	  analyses,	  significance	  was	  set	  at	  p≤0.05.	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Chapter	  3	  
Role	  of	  GM-­CSF	  in	  the	  Inflammatory	  Cytokine	  Network	  that	  Regulates	  
Neutrophil	  Influx	  into	  the	  Colonic	  Mucosa	  during	  Clostridium	  difficile	  Infection	  
in	  Mice	  	  Portions	  of	  this	  chapter	  have	  been	  previously	  published	  	  
McDermott	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  Role	  of	  GM-­‐CSF	  in	  the	  inflammatory	  cytokine	  network	  that	  regulates	  neutrophil	  influx	  into	  the	  colonic	  mucosa	  during	  Clostridium	  difficile	  infection	  in	  mice.	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Introduction	  
	   Clostridium	  difficile	  infection	  is	  associated	  with	  robust	  neutrophil	  recruitment,	  increased	  expression	  of	  inflammatory	  cytokines	  and	  chemokines,	  and	  marked	  damage	  to	  the	  intestinal	  epithelium(1-­‐7).	  GM-­‐CSF	  promotes	  myeloid	  cell	  recruitment(8-­‐12)	  and	  inflammatory	  cytokine	  production	  during	  mucosal	  inflammation(10,	  13),	  as	  well	  protecting	  against	  epithelial	  damage	  during	  colonic	  inflammation(13-­‐15).	  While	  recent	  studies	  in	  our	  lab	  have	  reported	  increased	  expression	  of	  GM-­‐CSF	  in	  response	  to	  C.	  difficile	  infection(5),	  the	  role	  of	  GM-­‐CSF	  during	  C.	  difficile	  colitis	  has	  not	  been	  directly	  investigated.	  In	  this	  chapter,	  we	  assessed	  the	  role	  of	  GM-­‐CSF	  in	  promoting	  inflammatory	  cytokine	  expression,	  neutrophil	  recruitment,	  and	  epithelial	  damage	  during	  C.	  difficile	  colitis.	  	  




Expression	  of	  GM-­CSF	  during	  C.	  difficile	  infection	  	   We	  used	  a	  C.	  difficile	  infection	  model	  adapted	  from	  a	  previously	  described	  mouse	  model	  of	  acute	  C.	  difficile	  infection.(6)	  Briefly,	  mice	  received	  the	  broad-­‐spectrum	  antibiotic	  cefoperazone	  in	  their	  drinking	  water	  for	  5	  days,	  were	  infected	  with	  spores	  from	  C.	  difficile	  strain	  630	  by	  oral	  gavage	  2	  days	  after	  the	  cessation	  of	  antibiotics	  and	  then	  followed	  for	  4	  days	  (Figure	  3-­‐1).	  C.	  difficile	  630	  infection	  causes	  relatively	  mild	  disease,	  and	  this	  strain	  was	  chosen	  to	  permit	  investigation	  of	  both	  proinflammatory	  and	  epithelial-­‐protective	  functions	  of	  GM-­‐CSF.	  Cefoperazone	  treatment	  and	  C.	  difficile	  challenge	  resulted	  in	  a	  significant	  decrease	  in	  total	  bacterial	  diversity	  in	  the	  colon	  that	  persisted	  for	  at	  least	  one	  week	  post-­‐antibiotic	  treatment	  (Figure	  3-­‐2)	  and	  the	  establishment	  of	  C.	  difficile	  colonization	  in	  the	  colon	  (Figure	  3-­‐2).	  Beginning	  at	  one-­‐day	  post-­‐infection,	  C.	  difficile-­‐infected	  mice	  began	  to	  lose	  body	  weight	  (Figure	  3-­‐2).	  Additionally,	  there	  was	  a	  statistically	  significant	  increase	  in	  GM-­‐CSF	  expression	  in	  the	  colon	  of	  C.	  difficile-­‐infected	  mice	  compared	  to	  uninfected	  mice	  (Figure	  3-­‐2),	  which	  was	  not	  seen	  in	  mice	  treated	  only	  with	  cefoperazone	  (data	  not	  shown).	  	  
Effect	  of	  anti-­GM-­CSF	  treatment	  on	  C.	  difficile	  infection	  and	  the	  intestinal	  
epithelium	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   To	  begin	  to	  investigate	  the	  role	  of	  GM-­‐CSF	  in	  the	  pathogenesis	  of	  C.	  difficile	  infection,	  mice	  were	  treated	  with	  a	  neutralizing	  anti-­‐GM-­‐CSF	  monoclonal	  antibody	  (MP1-­‐22E9),	  every	  other	  day	  beginning	  one	  day	  prior	  to	  infection	  (Figure	  3-­‐1).	  This	  treatment	  did	  not	  affect	  the	  low	  bacterial	  diversity	  in	  these	  mice	  (Figure	  3-­‐2),	  nor	  did	  it	  significantly	  alter	  the	  composition	  of	  the	  bacterial	  microbiome	  (data	  not	  shown).	  Although	  not	  statistically	  significant,	  there	  was	  a	  trend	  toward	  lower	  C.	  
difficile	  colonization	  levels	  and	  more	  modest	  weight	  loss	  during	  the	  course	  of	  disease	  in	  mice	  treated	  with	  anti-­‐GM-­‐CSF	  mAb	  (Figure	  3-­‐2).	  C.	  difficile	  infection	  induced	  robust	  expression	  of	  the	  IL-­‐22	  pathway	  in	  the	  colonic	  mucosa,	  including	  induction	  of	  RegIIIγ	  (Figure	  3-­‐3).	  There	  was	  a	  trend	  toward	  lower	  IL-­‐22	  expression	  levels	  in	  anti-­‐GM-­‐CSF	  treated	  mice,	  but	  neither	  IL-­‐22	  nor	  RegIIIγ	  expression	  was	  significantly	  lower	  in	  these	  mice	  (Figure	  3-­‐3).	  Thus,	  treatment	  with	  anti-­‐GM-­‐CSF	  did	  not	  exacerbate	  disease;	  rather,	  C.	  difficile	  colonization	  levels,	  weight	  loss	  and	  induction	  of	  the	  IL-­‐22	  pathway	  remained	  the	  same,	  if	  not	  slightly	  improved.	  	   One	  of	  the	  other	  salient	  features	  of	  C.	  difficile	  infection	  in	  the	  colon	  is	  the	  destruction	  of	  goblet	  cells	  in	  the	  epithelium.	  This	  loss	  was	  observed	  in	  both	  levels	  angiogenin-­‐4	  expression	  (Figure	  3-­‐3)	  and	  histologically	  evident	  changes	  (Figure	  3-­‐4).	  In	  the	  colon,	  angiogenin-­‐4	  is	  expressed	  solely	  by	  goblet	  cells	  in	  the	  crypts(41),	  and	  the	  expression	  of	  angiogenin-­‐4	  was	  significantly	  reduced	  in	  C.	  difficile-­‐infected	  mice.	  Loss	  of	  goblet	  cells	  from	  colonic	  crypts	  was	  evident	  in	  histology	  sections,	  with	  a	  marked	  reduction	  in	  these	  cells	  (denoted	  by	  their	  vacuoles)	  observed	  in	  both	  transverse	  and	  oblique	  sections	  (Figure	  3-­‐4).	  Treatment	  with	  anti-­‐GM-­‐CSF	  mAb	  did	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not	  significantly	  protect	  against	  loss	  of	  angiogenin-­‐4	  expression	  (Figure	  3-­‐3)	  or	  goblet	  cells	  (Figure	  3-­‐4)	  that	  occurred	  during	  C.	  difficile	  infection.	  	  	  
Effect	  of	  anti-­GM-­CSF	  treatment	  on	  inflammation	  and	  neutrophil	  recruitment	  
during	  C.	  difficile	  infection	  	   However,	  investigation	  into	  some	  of	  the	  specific	  inflammatory	  pathways	  associated	  with	  C.	  difficile	  infection	  revealed	  a	  role	  for	  GM-­‐CSF	  in	  driving	  inflammatory	  cell	  recruitment,	  most	  notably	  neutrophils.	  C.	  difficile	  630	  infection	  induced	  significant	  expression	  of	  the	  inflammatory	  cytokines	  IFNγ,	  IL-­‐1β,	  IL-­‐6	  and	  TNFα	  in	  the	  colon	  mucosa	  at	  four	  days	  post-­‐infection	  (Figure	  3-­‐5).	  Treatment	  of	  C.	  
difficile	  infected	  mice	  with	  anti-­‐GM-­‐CSF	  mAb	  resulted	  in	  significantly	  lower	  expression	  of	  IL-­‐1β	  and	  TNFα	  (Figure	  3-­‐5).	  There	  was	  no	  significant	  induction	  of	  IL-­‐12,	  IL-­‐23,	  IL-­‐17,	  IL-­‐10	  or	  TGF-­‐β	  in	  either	  group	  of	  infected	  mice	  (data	  not	  shown).	  Consistent	  with	  the	  leukocytic	  infiltrates	  evident	  in	  histological	  sections	  of	  C.	  difficile	  630	  infected	  mice	  (Figure	  3-­‐4),	  there	  was	  a	  significant	  increase	  in	  expression	  of	  the	  CC	  chemokines	  CCL2	  (MCP-­‐1)	  and	  CCL4	  (MIP-­‐1α)	  and	  the	  IFNγ-­‐inducible	  non-­‐ELR	  CXC	  chemokines	  CXCL9	  (MIG)	  and	  CXCL10	  (IP10)	  (Figure	  3-­‐6).	  Anti-­‐GM-­‐CSF	  treatment	  had	  no	  effect	  on	  expression	  of	  these	  chemokines.	  In	  contrast	  to	  CCL2,	  CCL4,	  CXCL9	  and	  CXCL10,	  anti-­‐GM-­‐CSF	  treatment	  significantly	  reduced	  expression	  of	  the	  ELR+	  CXC	  chemokines	  CXCL1	  (KC)	  and	  CXCL2	  (MIP-­‐2)	  (Figure	  3-­‐6).	  ELR+	  CXC	  chemokines	  are	  predominantly	  neutrophil	  chemotactic	  factors	  and	  contain	  a	  conserved	  amino	  acid	  sequence	  motif	  (glutamic	  acid-­‐leucine-­‐arginine,	  i.e.	  E-­‐L-­‐R)	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that	  immediately	  precedes	  the	  first	  cysteine	  residue	  near	  the	  amino-­‐terminal	  end	  and	  confers	  binding	  specificity	  to	  specific	  CXC	  chemokine	  receptors.	  Expression	  of	  both	  of	  these	  ELR+	  CXC	  chemokines	  in	  the	  colon	  following	  C.	  difficile	  infection	  was	  also	  associated	  with	  the	  influx	  of	  neutrophils	  into	  the	  parenchyma	  (Figure	  3-­‐4).	  Consistent	  with	  the	  lower,	  but	  still	  significant,	  expression	  of	  CXCL1	  and	  CXCL2	  in	  anti-­‐GM-­‐CSF	  treated	  mice,	  neutrophils	  were	  still	  evident	  in	  colonic	  mucosal	  sections,	  but	  their	  numbers	  were	  reduced	  (Figure	  3-­‐4).	  	  	  	   Inducible	  nitric	  oxide	  synthase	  (iNOS)	  is	  often	  associated	  with	  host	  antimicrobial	  responses,	  and	  can	  be	  expresed	  by	  a	  variety	  of	  cells	  including	  neutrophils(42,	  43)	  and	  intestinal	  epithelial	  cells.(44)	  iNOS	  was	  expressed	  in	  colonic	  tissue	  following	  C.	  difficile	  infection	  concomitant	  with	  the	  development	  of	  inflammation	  and	  neutrophil	  influx	  (Figure	  3-­‐4).	  Anti-­‐GM-­‐CSF	  treatment	  also	  resulted	  in	  a	  significant	  decrease	  in	  iNOS	  expression	  (Figure	  3-­‐6).	  	  	   Secretory	  leukocyte	  protease	  inhibitor	  (SLPI)	  is	  a	  well-­‐documented	  inhibitor	  of	  neutrophil	  elastase,	  and	  other	  serine	  proteases,	  is	  produced	  by	  epithelial	  cells	  and	  can	  protect	  against	  neutrophil-­‐mediated	  protease	  damage.(45-­‐49)	  Following	  C.	  
difficile	  infection,	  SLPI	  expression	  is	  significantly	  upregulated	  in	  the	  colonic	  mucosa	  (Figure	  3-­‐6).	  However,	  treatment	  with	  anti-­‐GM-­‐CSF	  significantly	  reduced	  expression	  of	  SLPI,	  concomitant	  with	  the	  reduced	  neutrophil	  influx	  in	  these	  mice	  (Figure	  3-­‐6).	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Figure	  3-­1.	  Experimental	  Timeline	  for	  Investigating	  the	  Role	  of	  GM-­CSF	  During	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Figure	  3-­2.	  Impact	  of	  Anti-­GM-­CSF	  Treatment	  on	  Clostridium	  difficile-­Induced	  
Disease.	  	  (a)	  Colonic	  microbiota	  diversity	  during	  C.	  difficile	  630	  infection	  (Day	  4).	  (b)	  C.	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Figure	  3-­3.	  Effect	  of	  anti-­GM-­CSF	  Treatment	  on	  IL-­22,	  RegIIIγ ,	  and	  Angiogenin-­
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Figure	  3-­4.	  Colonic	  Histopathology	  Following	  anti-­GM-­CSF	  Treatment.	  Photomicrographs	  of	  representative	  H&E-­‐stained	  oblique	  and	  transverse	  sections	  of	  colonic	  crypts	  from	  uninfected	  (untreated),	  C.	  difficile	  630	  infected	  (Day	  4)	  and	  C.	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Figure	  3-­5.	  Inflammatory	  Cytokine	  Expression	  in	  the	  Colonic	  Mucsoa	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Discussion	  	  	   This	  is	  the	  first	  reported	  investigation	  of	  the	  role	  of	  GM-­‐CSF	  in	  the	  cytokine	  network	  that	  regulates	  inflammation	  following	  C.	  difficile	  infection.	  In	  the	  current	  study,	  we	  observed	  reduced	  ELR+	  CXC	  chemokine	  expression	  in	  addition	  to	  evidence	  of	  decreased	  neutrophil	  recruitment	  following	  anti-­‐GM-­‐CSF	  treatment.	  GM-­‐CSF	  is	  a	  potent	  driver	  of	  mucosal	  inflammation	  in	  other	  disease	  settings,	  including	  the	  intestinal	  tract(25-­‐27),	  but	  has	  not	  been	  investigated	  for	  the	  pathogenesis	  of	  C.	  difficile,	  a	  toxin-­‐producing	  bacteria	  with	  distinct	  virulence	  mechanisms	  from	  attaching	  and	  effacing	  enteric	  bacteria.	  GM-­‐CSF	  has	  been	  reported	  to	  promote	  neutrophil	  recruitment	  during	  acute	  pulmonary	  inflammation(8-­‐11)	  and	  is	  also	  required	  for	  full	  recruitment	  of	  neutrophils	  and	  production	  of	  CXCL1	  (KC)	  in	  an	  experimental	  model	  of	  otitis	  media(50).	  Within	  the	  gut,	  GM-­‐CSF	  has	  also	  been	  shown	  to	  promote	  neutrophil	  recruitment	  during	  2,4,6-­‐trinitrobenzenesulfonic	  acid	  (TNBS)-­‐colitis(12).	  Additionally,	  one	  study	  suggests	  that	  GM-­‐CSF	  can	  function	  directly	  as	  a	  chemoattractant	  for	  neutrophils(12).	  While	  we	  have	  demonstrated	  that	  GM-­‐CSF	  is	  expressed	  in	  the	  colon,	  and	  previous	  studies	  have	  demonstrated	  colon-­‐localized	  effects	  following	  intraperitoneal	  injection	  of	  the	  anti-­‐GM-­‐CSF	  mAb	  used	  in	  the	  current	  study(51),	  we	  have	  no	  evidence	  in	  this	  study	  that	  the	  site	  of	  activity	  of	  our	  anti-­‐GM-­‐CSF	  mAb	  is	  the	  colon	  itself.	  GM-­‐CSF	  is	  a	  critical	  factor	  for	  the	  survival	  of	  infiltrating	  neutrophils	  in	  a	  tissue,	  protecting	  them	  against	  apoptosis,	  but	  it	  also	  plays	  a	  role	  in	  the	  differentiation	  of	  neutrophils	  from	  bone	  marrow-­‐derived	  precursors.	  Thus,	  an	  important	  site	  of	  GM-­‐CSF	  activity	  during	  C.	  difficile	  infection	  may	  be	  the	  bone	  marrow.	  Altogether,	  our	  data	  strongly	  support	  the	  concept	  that	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GM-­‐CSF	  can	  regulate	  neutrophil	  chemokine	  expression	  and	  neutrophil	  recruitment	  during	  C.	  difficile	  colitis	  although	  its	  activity	  may	  include	  extra-­‐intestinal	  regulation	  of	  neutrophil	  biology.	  	  	  	   In	  addition	  to	  reduced	  ELR+	  CXC	  chemokine	  expression,	  we	  also	  observed	  decreased	  expression	  of	  inflammatory	  cytokines,	  most	  notably	  TNFα,	  during	  C.	  
difficile	  colitis	  following	  treatment	  with	  anti-­‐GM-­‐CSF.	  TNFα	  expression	  has	  been	  demonstrated	  to	  be	  largely	  dependent	  upon	  GM-­‐CSF	  signaling	  in	  chemical(11)	  and	  microbial(10)	  models	  of	  acute	  pulmonary	  inflammation.	  GM-­‐CSF	  also	  promotes	  TNFα	  production	  during	  middle-­‐ear	  inflammation(50).	  Inflammatory	  cytokine	  expression	  during	  chemically-­‐induced	  colitis	  is	  also	  dependent	  upon	  GM-­‐CSF(13).	  Consistent	  with	  other	  reports,	  our	  data	  strongly	  suggest	  that	  GM-­‐CSF	  promotes	  inflammatory	  cytokine	  expression	  during	  C.	  difficile	  colitis.	  	   Numerous	  studies	  have	  reported	  an	  epithelial-­‐protective	  function	  for	  GM-­‐CSF	  during	  mucosal	  inflammation(13-­‐15,	  28,	  29).	  In	  the	  absence	  of	  GM-­‐CSF,	  colonic	  ulceration	  and	  overall	  intestinal	  pathology	  in	  response	  to	  DSS	  is	  significantly	  increased(13,	  14).	  Additionally,	  during	  Citrobacter	  rodentium	  infection,	  GM-­‐CSF	  serves	  to	  protect	  against	  the	  development	  of	  severe	  intestinal	  pathology(15).	  In	  the	  current	  study,	  however,	  we	  did	  not	  observe	  increased	  epithelial	  damage	  during	  C.	  
difficile	  infection	  following	  anti-­‐GM-­‐CSF	  treatment	  or	  further	  reduction	  in	  expression	  of	  the	  goblet	  cell-­‐associated	  antimicrobial	  peptide	  angiogenin-­‐4(41),	  suggesting	  colonic	  goblet	  cells	  were	  not	  under	  additional	  stress	  following	  anti-­‐GM-­‐CSF	  treatment.	  Altogether,	  this	  may	  reflect	  a	  difference	  in	  the	  nature	  of	  the	  primary	  
  68 
source	  of	  epithelial	  damage	  during	  infection,	  C.	  difficile	  toxins(21-­‐23),	  compared	  to	  other	  mechanisms	  of	  epithelial	  damage.	  	   One	  model	  that	  could	  explain	  the	  association	  between	  reduced	  neutrophil	  recruitment	  and	  reduced	  cytokine	  and	  chemokine	  expression	  seen	  following	  anti-­‐GM-­‐CSF	  treatment	  is	  that	  neutrophils	  may	  also	  be	  a	  cellular	  source	  of	  inflammatory	  cytokines	  during	  C.	  difficile	  infection.	  Neutrophil	  recruitment	  into	  the	  colonic	  mucosa	  and	  production	  of	  a	  "storm"	  of	  inflammatory	  cytokines	  are	  key	  features	  of	  the	  pathogenesis	  of	  the	  disease(1-­‐7,	  24,	  30).	  C.	  difficile	  toxins	  TcdA	  and	  TcdB,	  as	  well	  as	  other	  factors	  from	  C.	  difficile,	  can	  elicit	  IL-­‐1β,	  TNFα,	  CC	  and	  CXC	  chemokine	  production	  from	  macrophages	  and	  epithelial	  cells	  in	  vitro,	  but	  neutrophils	  have	  not	  been	  investigated	  as	  a	  cellular	  source(31-­‐37).	  Neutrophils	  are	  capable	  of	  producing	  IL-­‐1β	  and	  TNFα,	  as	  well	  as	  chemokines(52,	  53).	  Additionally,	  GM-­‐CSF	  not	  only	  serves	  to	  prevent	  neutrophil	  apoptosis,	  but	  also	  modifies	  neutrophil	  behavior	  and	  can	  promote	  the	  production	  of	  neutrophil	  chemokines(52,	  54).	  However,	  other	  studies	  in	  our	  laboratory,	  using	  anti-­‐Gr1	  to	  deplete	  Gr1+	  cells	  during	  C.	  difficile	  VPI	  10463	  infection	  in	  mice,	  found	  no	  change	  in	  the	  levels	  of	  IL-­‐1β,	  TNFα	  or	  CXCL1	  expression	  following	  anti-­‐Gr-­‐1	  treatment(55).	  One	  caveat	  of	  this	  observation	  is	  that	  this	  strain	  of	  C.	  difficile	  produces	  higher	  levels	  of	  toxins,	  resulting	  in	  a	  more	  severe	  disease	  with	  more	  extensive	  epithelial	  damage(6,	  7,	  24).	  Thus,	  additional	  cellular	  pathways	  of	  IL-­‐1β,	  TNFα	  or	  CXCL1	  expression	  may	  be	  induced	  when	  toxin	  levels	  are	  higher.	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